Skip to main content

Talk Bio

Actionable Insights Powered by AI

Search This Blog

About

Showing posts with the label UpToDate Expert AI

Posts

General-purpose large language models outperform specialized clinical AI tools on medical benchmarks, Nature Medicine study finds

on June 17, 2026

ChatGPT Claude clinical AI clinical queries Gemini 3.1 Pro general-purpose GPT-5.2 HealthBench Languages medical benchmarks MedQA Nature Medicine OpenEvidence RCQ Study models UpToDate Expert AI

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Archive

July 2026197
June 2026189
May 2026217
April 2026257
March 2026233
February 2026175
January 2026261
December 2025151
November 2025147
October 2025222

September 2025190
August 2025161
July 2025130
June 2025159
May 2025174
April 2025191
March 2025205
February 2025198
January 202539

Show more Show less

Tags

United States Food and Drug Administration Clinical Trials Approved Obesity Neoplasms gene therapy Glucagon-Like Peptide 1 Vaccines Investments Phase 3

AstraZeneca acquisition Pfizer China Eli Lilly sanofi Artificial Intelligence Infrequent Market Merck Pharma Roche (company) layoffs Novartis Drug Industry Drug Discovery Biological Factors SmithKline Beecham manufacturing IPO eli lilly Leadership CEO Drug Development Autoimmune Diseases Cell Therapy restructuring Nordisk Transplant Registry Unified Management Program Appointments Wegovy Acquisition Eli Funding Weight Loss expansion Inhibitor Overall Survival drug price Biotechnology Safety COVID19 (disease) U.S. AbbVie Policy CHARGE Syndrome United States therapeutic autologous dendritic cells Malignant neoplasm of breast Muscular Dystrophy, Duchenne Non-Small Cell Lung Carcinoma Novo Nordisk Immunology Biogen R&D methionine Antibody-Drug Conjugates Centers for Disease Control and Prevention (U.S.) Sales - occupational activity Zepbound semaglutide Keytruda Precision Medicine Industry Oral cavity Partnership Progression-Free Survival Alzheimer 's disease Collaboration Dosage Forms Amgen Biopharma Health care facility Immunotherapy Regeneron Drug Approval M&A Solid Neoplasm milestone payments Accelerated CAR-T financial results Administration occupational activities Nasdaq Prices Board of Directors Clinical Research Effectiveness Malignant neoplasm of lung Changing Elevidys Multiple Myeloma Phase 3 Clinical Trials biotech pipeline rejection Antibodies, Bispecific Biological Science Disciplines PDUFA earnings innovation Biosimilars EU Moderna Staff UK Weight-Loss Agents ACIP AI-driven Biological Markers Cancer Therapeutic Procedure Phase 2 RFK Jr. Schizophrenia Trump administration BioNTech Gene Modification Gilead Growth Myers clinical development public health medicine (field) Antibodies J&J Takeda in vivo public entity trends qualifier Advisory Committees Clearance Clustered Regularly Interspaced Short Palindromic Repeats Myers Squibb 2025 AI drug discovery Capital Financial cost Johnson & Johnson Ozempic Phase 2 trial Rare Diseases genentech Bayer Metsera biopharma Medicare Phase 2 Clinical Trials Phase 3 trials Pricing Radiopharmaceuticals Series A US concerns dosing platform production research Advice Dermatitis, Atopic Dupixent Malignant neoplasm of prostate Monoclonal Antibodies Programs - Publication Format RFK gene clinical trial failure competition squibb Cardiovascular Diseases Diabetes NIH Mouse Phase 3 Trial Phase 3 trial Revolution Medicines Study on Hold optimization pembrolizumab Astellas Cautionary Warning Colorectal Carcinoma Deferred Frequency of Responses Gilead Sciences Health Inflammatory Bowel Diseases Kidney Diseases Malignant Neoplasms Pancreatic carcinoma Phase III Series Transition Mutation royalties venture capital Agonist Alopecia Biosciences Blackfoot language Diabetes Mellitus, Non-Insulin-Dependent Hims MASH Ophthalmology specialty Q3 Series B development aspects licensing agreement pharmaceutical manufacturing Amyotrophic Lateral Sclerosis Autoimmune Daiichi Evaluation Failure (biologic function) Legal patent Parkinson 's disease Small cell carcinoma of lung net loss supply chain CDMO Eisai HHS Insilico Medicine Medicaid Metabolic Diseases Mounjaro RNA Rheumatoid Arthritis Sankyo Senate Study models daraxonrasib regulatory safety profile tariffs ASCO Adverse event Antineoplastic Agents Biotherapeutics Boehringer Ingelheim Discontinuation (procedure) Epilepsy European (ethnic group) Health Policy Labels (device) Leqembi Medical Devices Merck KGaA NDA Neuroscience discipline Pharmacotherapy Preventive monitoring RNA Interference Robert F. Kennedy TNFRSF19 gene Telemedicine cardiometabolic government melanoma orforglipron pharmaceutical tariffs subcutaneous venture 2026 Asthma Bio BioMarin Burning Mouth Syndrome CBER CD276 gene CFO Clinical Data Duchenne Eczema Enhertu Flagship IGA Glomerulonephritis Malignant neoplasm of urinary bladder Muscular Dystrophy Mutation News [Publication Type] Recommendation SMPX gene Ulcerative Colitis acquisitions federal financing characteristics leadership change milestones obesity drug ovarian neoplasm regulatory approval upfront payment Bispecific CDER Cells Child Complete Discover Drops - Drug Form Endpoints Foundayo Hypertensive disease Immunotherapy for cancer Japan Liver diseases Malignant neoplasm of stomach Multiple Sclerosis Nance-Horan syndrome North Carolina Pauses Proteinuria RNA, Small Interfering Respiratory syncytial virus Response process Risk Severe (severity modifier) Technology alpha 1-Antitrypsin Deficiency alpha 1-antitrypsin cash runway commercialization cost-cutting diagnostics patient deaths submission trials BTK inhibitor Benefit CAR-T therapy Combined Commission Confirmation Efficiency Facility (object) Financial savings Germany IL31RA gene LB-102 Leukemia, Myelocytic, Acute MFN Mediation Myasthenia Gravis Otsuka Pediatric brand name Psoriasis RNA, Messenger Replimune Robert F. Kennedy Jr. Target cellular targeting direct-to-consumer early-stage medtech reverse merger strategic alternatives tirzepatide Adult Alzheimer 's Amylin Antibiotics Board appointment Breakthrough Therapy CHMP COPD Cancer Research Chronic disease Clinical Dosage Drugs, Orphan Homo sapiens Idiopathic Pulmonary Fibrosis Impact food supplement Ivonescimab Johnson and Johnson Machine Learning Makary Myeloid Leukemia, Chronic Neurodegenerative Disorders PCSK9 inhibitor PD-L1 RETINITIS PIGMENTOSA 1 Series B funding Surgical construction Vaccine Safety Vanda Pharmaceuticals Weight maintenance regimen White House biobucks drug safety drugmakers healthcare technology immuno-oncology merger oral SERD portfolio radioligand therapy treatment-resistant depression uniQure ATTR-CM Access Agentic AI Antipsychotic Agents Automation BARDA Budgets Chronic Kidney Diseases Combined Modality Therapy Detection Eikon Elderly (population group) Exit File (record) Generic Drugs Genomics HIV HIV prevention Hallucinogens Hidradenitis Suppurativa Identifier LDL-C Lenacapavir Manufacture Mucopolysaccharidosis II NVIDIA Narcolepsy Opdivo Pharmaceutical Services Phase Phase 1 (qualifier value) Phase 1b Placebos Precision - temporal Product containing glucagon-like peptide 1 receptor agonist (product) Progressive Psilocybin Pulmonary Fibrosis Pulmonary arterial hypertension RNA Editing Retirement Revenue Scientific Advisory Board Series B financing Small Molecule Spinal Muscular Atrophy Toxicity aspects Veradermics Wegovy pill Withdraw (activity) approvals biotech startups cash position corporate digital health discontinued executive order inhibitors lawsuit patent cliff private equity resignation royalty Alnylam Anemia, Sickle Cell Attitude Bankruptcy Biomechanical compliance Biotech Layoffs Boehringer Chief Medical Officer Contraceptives, Oral ESMO Evidence First line treatment Generalized Hematologic Neoplasms Huntington 's disease Incyte Infant Inflammation Injury of liver Insmed Intellia Ipsen J.P. Morgan Healthcare Conference JPM26 Letter [Publication Type] Licensing Manufacturing Facilities Metastatic castration-resistant prostate cancer Multiple Acyl Coenzyme A Dehydrogenase Deficiency Myasthenic Syndromes, Congenital Nation National Security Neurology speciality Partner in relationship Peptides Prasad Priority Review Regenxbio Response Letter Review [Publication Type] Sectioning technique Servier Shakeup SpringWorks Stock Surge Surgical aspects T-cell engager Tavneos TrumpRx acute aspects of adverse effects biotech industry camizestrant cancer drugs cardiometabolic diseases erbB-2 Receptor manufacturing issues mental health nivolumab partnerships revenue growth surge targets AAVS1 gene AMT-130 Abivax Achondroplasia Adangme language Aktis Alkermes Amlitelimab Antagonist muscle action Antisense Oligonucleotides Application procedure Bavarian Nordic Big Pharma Billion Biotech IPOs Blood - brain barrier anatomy BridgeBio CLL CNPV CagriSema Cardiovascular system Chronic Lymphocytic Leukemia Chronic Spontaneous Urticaria Chronic multifocal osteomyelitis Cobenfy Complete Response Letter Conditional Congress (U.S. Legislature) Contract agreement Cystic Fibrosis DNA Integration Diabetes Mellitus, Insulin-Dependent Diffuse Large B-Cell Lymphoma Disease Outbreaks Drug Delivery Systems ESR1 gene Enliven Therapeutics Epidermal Growth Factor Receptor Europe Event Exelixis Extension Eylea Gardasil Glycogen storage disease type II Glycosylated hemoglobin A Head Heart failure Hetlioz Hong Kong Illumina Influenza Insulin MAHA Malignant neoplasm of endometrium Migraine Disorders Nuvalent ORR OpenAI PAH PFS PREP gene Patient Death PhRMA Prader-Willi Syndrome Presenile dementia Relapsing course Rinvoq Roivant Sandoz Seizures Supplement Teva Trump tariffs VK2735 Vinay Prasad Wave Life Sciences analysts asset assets bidding war biology (field) biomanufacturing delays executive appointments first generative AI generics giredestrant immunotherapeutics jet lag disorder launch manager monthly oncology pipeline pharmaceutical innovation precision oncology retatrutide sNDA shionogi sonelokimab startup strategic strategic collaboration upfront AI platform AI-powered Agencies Akeso Anemia Angioedemas, Hereditary Apellis Argenx Atrial Fibrillation Autistic Disorder CNS disorder Capricor Therapeutics Cessation of life Chief Chief Financial Officer Chinese Language Crohn 's disease Decision Denali Drug Prescriptions Forbion Fund Raising GLP-1 receptor GZMH gene Genmab Geographic Atrophy HER2-negative HPV vaccine Heather Flick Melanson Hepatitis B IPOs Imfinzi Import In complete remission Indirect Indonesian language Inflammatory disorder Injection of therapeutic agent Innovent Biologics Ionis Pharmaceuticals Jazz K-ras Oncogene LDL Cholesterol Lipoproteins Leukemia LillyDirect Liquid Biopsy Liver Failure, Acute Lundbeck Lupus Vulgaris Lymphoma Maintenance Marty Makary Measles-Mumps-Rubella Vaccine Mental deterioration MoonLake Nerve Degeneration Neuroinflammation New Jersey Nitroglycerin/Sodium Citrate/Ethanol Solution Opioids PD-1/VEGF Padcev Paul Hudson Phase 1b trial Phase 3 clinical trial Phase I Clinical Trials Pioneering Post-Traumatic Stress Disorder President brand of dental material Projections and Predictions RMAT Regenerative Medicine Remote Retinitis Pigmentosa Secretary Sentiment Seqirus Shanghai Statistical Significance TIGIT gene TYK2 gene Tagrisso Talzenna Thyroid associated opthalmopathies Tolebrutinib Translucent Triglycerides Tubulis Ultragenyx Urinary tract infection Window (physical object) Zealand Pharma annual biotech partnerships developability diranersen drug review exophthalmos producing substance factor IX independent review interleukin-6 mRNA flu manufacturability minoxidil molecular glue onshoring oral semaglutide patent infringement perioperative personalized therapies pilot program pre-funded primary endpoint real-world reorganization settlement shareholder shipment summit 3-Methylglutaconic aciduria type 2 340B AACR 2026 ADC ADCs AI models AI-enabled AKTS ALV-100 ALV-200 Acquisition (action) Adolescent (age group) Advanced Melanoma Altimmune Alumis Alveus Therapeutics AnaptysBio Anthropic Anticoagulants Ascletis Asymmetric Septal Hypertrophy Australia Autoimmune thrombocytopenia Avalyn B-Lymphocytes BCR-ABL1 BNT327 Biologics License Application Biosecure Act Blenrep Bourla Brain Neoplasms Buckham CE Mark CEOs CIDRAP COVID CSO CVR California Cambridge Camzyos Canada Cancer Vaccines Cancer of Neck Clinical Nurse Specialists Co. Compass Pathways CytomX DOGE Datroway Deafness Deep molecular response Department of Health and Dependovirus Disease-Free Survival Disorder of eye Ditiocarb Durham ER-positive Effect Elamipretide Empaveli Event-Free Survival Evotec SE Failed Fast Track GIPR gene Galapagos Generative AI Gomekli Guanosine Monophosphate Halda Therapeutics Halozyme Hannah Anderson Head of US Healthy Heart Diseases Hereditary Diseases Hyperphagia Hypertriglyceridemia Immunization Immunostimulating conjugate (antigen) Impaired India Inflation Reduction Act Inosine Triphosphate J.MD Jr. Kailera Kardigan Kelonia Therapeutics Labcorp Leerink Partners Legend Biotech License Application Licensing Deal Litigation Long-term Longevity Lung diseases MHRA Macular edema due to diabetes mellitus Malignant neoplasm of kidney MariTide-like Maziar Mike Doustdar Meeting Menopause Metabolic Misinformation Molecular Response Most-Favored-Nation Muscular Dystrophies, Limb-Girdle Myelocytic NECTIN4 gene NLRP3 inhibitors Neoplasm, Residual Novavax ODAC PARP1 gene PDCD1 gene Parabilis Medicines Pathology Performance Personnel Selection Phase 1 trial Physicians Platform Post-Hoc Live Prescription procedure Project Protein Degradation, Metabolic Q4 2025 R-Series RGX-121 RIPTAC RNA therapeutics RVMD Reaction Regulation Research Projects Retinal Diseases Rick R. Suarez Rocket Science Score Series D Sibeprenlimab Sotyktu Standard of Care Stem Cell Therapy Stock Decline Surveys Syfovre T-Lymphocyte TMEM79 gene Tecentriq Triple Negative Breast Neoplasms Trodelvy Twice a day Type B meeting Uncertainty United States Federal Trade Commission VDPHL01 Vaccine Integrity Project Validation Vascular Endothelial Growth Factor A Ventyx Biosciences Viking Virginia manufacturing facility WDR20 gene Wilmington Delaware Winrevair Worker WuXi AppTec Yeztugo Zymeworks aldosterone synthase inhibitor asciminib authorization baxdrostat capabilities capital markets chain disruption chronic collaboration termination commercial coverage - financial contract dealmaking deals decision letter departure - ActRelationshipType deramiocel deruxtecan disbanded drug discounts drug market enforcement engagers enlicitide enzalutamide equity financial first-line focal onset seizures funding grant genetic medicines human license agreement mRNA Vaccine muscle-invasive bladder cancer negotiation obesity pill once-daily phase advance protocol preclinical data protein degrader public health policy radiopharma ras Oncogene recommendation change regulatory submission regulatory uncertainty resubmission single-dose schedule small-cell lung cancer stocks strategic review survival tasimelteon tolerability tonlamarsen trastuzumab upadacitinib uridine triacetate user fees valuation venetoclax workforce reduction zanzalintinib 130-nm albumin-bound paclitaxel 2023 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide AACR ABVX AI drug development AI model ALS AP01 Acceleration Adjuvant Therapy Affordability Agios Alcon Alector Alexion Alternative Androgenetic Alopecia Anktiva Antengene Antibody-Drug Apnimed Apogee Therapeutics Arvinas Assembly (construction) Attention deficit hyperactivity disorder Audit Committee AutoInjector Autoimmune hemolytic anemia Automobiles BEACON-IPF Bain Capital Beak Beyfortus Biomedicines Blindness Blood Coagulation Disorders Board Appointment Bovichtus Brazil Breakthrough Therapy Designation Brinsupri CDC CDE COMP360 CRLs Capital Management Capsid Carcinoma breast stage IV Cardiomyopathies Carlyle Casgevy Cash Celcuity Cerebrovascular accident Cervical Atlas Chief Legal Officer Childhood Vaccines Chronic pain Clinical Failure Clinical Trial Failures Clinician Complete Response Letters Compound Confirmatory Trial Contraceptives CordenPharma Corporate governance Creative Biolabs Cytokinetics DKK1 gene DMD DNA De Novo Depletion Depressive disorder Diabetic Retinopathy Dianthus Therapeutics Disease Progression Diversity Drug Regulations EBITDA EGFR-mutated EHA ELAVL2 gene Early Diagnosis Ebvallo Ecosystem Eli Lilly backing Employee Enflonsia Engaged to be married Episodic Express Scripts Family Turdidae (organism) Farxiga FibroGen Funds GLP-1/GIP dual agonist GLP-1s Gene Silencing Glaucoma Glioblastoma Gross (qualifier value) Groups Gubra Hearings Hemoglobin A1c measurement Hengrui Henlius Hodgkin Disease Hot flushes Hypercholesterolemia Hypersensitivity Hypertrophic Cardiomyopathy IL33 protein, human IRA ImmunityBio Immunogenicity (package insert) Immunovant Increase InduPro * * Infantile Severe Myoclonic Epilepsy Injectables Insurance Ira (eukaryote) JPM Jaypirca Jemperli Journavx KOL Kisunla Lab-in-the-Loop Lecanemab Legal License Liver Liver carcinoma Lp(a ) Lupus Erythematosus, Systemic Lynkuet M&A activity MET-097i MYELODYSPLASTIC SYNDROME MacroGenics Malaria MapLight Therapeutics Marketing Authorization Medical Research activity Merck & Co. Midomafetamine Mississippi (geographic location) Muscular Dystrophy, Facioscapulohumeral Myocarditis NAMs NYSE Nektar Therapeutics Neurocrine Neuromuscular Diseases Neuropsychiatry New New Drug Application Nurix Odyssey Therapeutics Ogsiveo Oligonucleotides Oral Organoids PANSS PD-1xVEGF Patient access Pediatric Disorder Pennsylvania Personalized Peter Marks Phase 1/2 trial Phase 2 clinical trial Phase 2 trials Phase 2b Phase I Plant seeds Pliant Poly(ADP-ribose) Polymerase Inhibitors Pounds Praxis Precision Medicines Preclinical Prediction Preventive Health Services Primary Biliary Cholangitis Primary Myelofibrosis Protac Psoriasis Area and Severity Index Clinical Classification Psychological inhibition Q1 2026 Q2 2025 Q3 2025 Quality RAS RAS-driven cancers RDEP ROS1 gene Rakovina Real-world Evidence Recovery - action Recursion Regulatory Affairs Regulatory Setback Renal Cell Carcinoma Reparative closure Research Personnel Respiratory physiology Reversal Robotics SPAC SanegeneBio Series A financing Series C Series D financing Sharing (Social Behavior) Skyrizi Small Interfering Sofinnova Stealth BioTherapeutics Structure Therapeutics Subcutaneous Injections Subgroup A Nepoviruses Suspensions TMALIN TNBC TROP2 TSLP gene Tablet Dosage Form Terns Tessera Transitory UCB UX111 Ultomiris Unresectable VRBPAC VTX3232 VTX958 Vabysmo Vaccination Valneva Vas Narasimhan ViiV Healthcare Vinay Vital capacity Vitiligo Vyvgart Wall Street Journal Workforce Reduction World Health Organization YL201 Zolgensma Zorevunersen Zynlonta abbott agonists alfa alixorexton altretamine/cisplatin/cyclophosphamide protocol antitrust atezolizumab biotech collaboration biotech sector bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine board changes bounce business career cabozantinib chief of chikungunya vaccine clinical endpoints conditions contingent value right court data privacy datasets decline digital transformation digital twins docetaxel domvanalimab executive leadership expense federal judge gedatolisib high-risk immune-mediated diseases leukemia mCRPC measles mechanism pathway mitapivat muscle preservation neladalkib nervous system disorder nrSPMS oncology partnership pandemic preparedness patent settlement payers pharmaceutical companies pharmaceutical marketing pharmaceutical sales pharmaceutical supply chain platforms plunge proposal - intent protein degraders rally rates real-world data real-world evidence regulatory compliance remibrutinib reshoring revenue guidance roxadustat rumors scalability seconds shareholders shutdown skipping spending stock crash strategic shift takeover talks talazoparib targeted therapies tariff triple agonist update user fee value-based care vedotin vusolimogene oderparepvec women 's health zidesamtinib zolucatetide AD109 AI biotech AI factory AI healthcare AI protein design AI-designed drug ALK gene AP02 ARD-101 ASC30 ASCO26 ASGCT ATR Inhibitor Aardvark Therapeutics Acelyrin Acute lymphocytic leukemia Acute onset pain AdvanCell Advanced phase Advocacy Age related macular degeneration Agios Pharmaceuticals Albert Americas Amvuttra Amylin Analog Amyloid beta-Peptides Amyloidosis Angelini Pharma Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antiviral Agents Apellis acquisition Apolipoprotein E4 Apolipoproteins B Arcellx Arcus Arcus Biosciences Arrowhead Pharmaceuticals Ascendis Pharma Atacicept AtaiBeckley Atara Ataxia Aurora Therapeutics Avidity Biosciences Awareness B-Cell Lymphomas BRUIN BTK Base Editing BeOne Medicines Beijing Bhattacharya Biktarvy Biliary Tract Cancer Bio-Techne BioNeMo Biohaven Biological Assay Biomedical Research Black Populations BlueRock Therapeutics Blujepa Body mass index procedure Burden CBO CD19 Antigens CD3 Antigens CDK2 protein, human CDK4/6 inhibitor CNP gene COAST CRDMO CRO Caldera Therapeutics Carboxyamidotriazole Orotate Cardiff Oncology Cardiology discipline Cardiovascular Agents Cardiovascular event Carvykti Centessa Pharmaceuticals Change, Organizational Charles ChatGPT Chief Commercial Officer Chief Operating Officer Chikungunya Fever Childhood Chronic Obstructive Airway Disease Chugai Claudin-18 Isoform A2 Clinical Trial Design Commissioner Communicable Diseases Complement Inactivating Agents Complicated Concentra Biosciences Congenital Construction worker Conventional (Clear Cell) Renal Cell Carcinoma Crackdown Crinetics CureVac Cylembio Cystic Fibrosis Transmembrane Conductance Regulator DILI DLL3 gene Darzalex Datopotamab deruxtecan Deal Value Death of child Deficiency Demand (clinical) Dexcom Diabetes Mellitus Diagnosis Does speak Dominance Drug Shortage Drug withdrawal syndrome DualityBio Dyne Therapeutics Dyslipidemias Dystrophin ECCO ENPP1 gene ENTR-601 Earendil Labs Edema Edgewise Therapeutics Eliquis Emma Walmsley Employer Endometriosis Erasca European Hematology Association ( Expectations Eye Drops Eylea HD FCGRT gene FDA-approved Fabry Disease Familial chylomicronemia syndrome Fibromatosis, Aggressive Fierce Florida France Freezing Functional Fyodor G-Protein-Coupled Receptors GE HealthCare GLP-1 pill GLP-1/GIP GLP-1/GIP receptor agonist Gastric Inhibitory Polypeptide General Meeting Genome Genome Editing Glycogen Storage Disease Type IIb Gout Suppressants HBr HHS layoffs HLD-0915 HRSA Health Care Reform Health Planning HealthBench Hearing Hemab Therapeutics Hematologic Tests Hengrui Pharma Hims & Hers Holdings Holly Springs Hormone Therapy Hypercholesterolemia, Familial Hyperphosphatemia (disorder) Hypertrophic obstructive cardiomyopathy Hypothalamic obesity Imcivree Imdelltra Immune Immune Medicines Immunologic Adjuvants Immunome Improvement Incretins Indication of (contextual qualifier) Induce (action) Inflation Influenza virus vaccine Ingelheim Inhibrx Interferes with Interleukin-13 Interleukin-17 Intrathecal Route of Drug Administration Irish (ethnic group) Isomorphic Labs Ixchiq Jakafi Janus kinase Janus kinase inhibitor Jefferies Jeffrey Jennifer Doudna KRAS NP_004976.2:p.G12C Kailera Therapeutics Kelun-Biotech Kinaset Therapeutics Kirin Krazati Kymera Kyowa Laboratory Laboratory test finding Legos Litifilimab Liver Failure Liver and Intrahepatic Biliary Tract Carcinoma Localized Logistics Luke Miels Lupus Erythematosus Lupus Nephritis Lymphodepletion Therapy Lymphoma, Follicular Lytenava MC4R protein, human Madrigal Pharmaceuticals Maria Sainz Marty Maryland (geographic location) Massive Medical Specialities Medical service Medicare Part D MeiraGTx Menin Inhibitor Menkes disease Menlo Ventures Mental Depression Merus Metastatic Prostate Carcinoma Midline (qualifier value) Mortality Vital Statistics Motion Sickness Myasthenia Gravis, Generalized Myasthenic Syndromes Myopia N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide NIH Narcolepsy type 1 Nasal Spray Nasdaq KARD Neoplasm Metastasis Nephrology Speciality Neuphoria Neuregulins Neurodevelopmental Disorders Neurosecretory Systems Nkarta Non-Insulin-Dependent Non-Muscle Invasive Bladder Neoplasms Novavax 's Nucala Nxera Pharma OLN324 Obefazimod Obesity Drug Odyssey Olezarsen Oncolytics Options Orphan Drug Designation Oura Oura Ring PBMs PCSK9 protein, human PDE3/4 inhibitor PIK3CA gene PYRUKYND Pain management Parity Personnel Turnover Pharma Industry Pharmaceutical Group Pharmaceutical merger Pharmacovigilance Pharmacy facility Phase 1/2 data Phase 3 failure Phase II Pipeline Development Piperine Extract (Standardized) Pirtobrutinib PreCheck Precision immunology Pressure- physical agent Primary Prevention Privacy Prophylactic treatment Protein Domain Protein-tyrosine kinase inhibitor Proteomics Prothena Psychotic Disorders Public Offering Pulse Biosciences R&D pipeline RAP-219 RAPT REMS RNA, Circular Rani Therapeutics Rapport Therapeutics Ras Inhibitor Rating (action) Recordati Recurrent respiratory papillomatosis RegenXBio Regulatory Action Reimbursement RemeGen Repatha Repertoire Research Infrastructure Respiration Disorders Restrictions Revenue Decline Rexulti Rezpeg Rhythm Pharmaceuticals Richard Pazdur Rocatinlimab Rosnilimab Rybrevant SLC6A8 Inhibitor RGX-202 SNCG gene STELLAR-303 Samsung Biologics San Diego Sarclisa Saxenda Scholar Rock Science of Chemistry Screening for cancer Secondary malignant neoplasm of pancreas Secretary Nomination Security - service Senate hearing Shingrix Sleep Apnea Syndromes South Korea South San Francisco Spikevax SpinCo ' Spinal Cord Injuries Spinocerebellar Spinraza Stabilizer - function Stelara Stifel Substance Use Disorders Supernus Pharmaceuticals Supreme Court Systemic Systemic Scleroderma T-Cell Receptor T-cell engagers TERN-701 TNFSF15 gene TREM2 TUB-040 TYK2 inhibitor Taiwan Takeover Team Testing Therapeutic immunosuppression Thermo Fisher Thermo Fisher Scientific Tradipitant TransCon Transection (procedure) Trimonthly Trump Truqap Tryngolza UPenn Unable to walk (finding) Uncontrolled United Kingdom United States National Institutes of Health UnitedHealth Group Unresponsive to Treatment Uplizna UroGen VAERS VERVE-102 VG-3927 VX-264 Vaxart Venclexta Vepdegestrant Verona Viking Therapeutics Viral Vector Viridian Vision Voyxact Vyne WVE-007 Wages Welireg Western patients Winter Park Woman Workers WuXi Xtandi Zenas BioPharma Ziftomenib Zurzuvae adaptation addiction advanced therapies aficamten amendment antibody engineering asthma drug augmented avacopan azacitidine bemdaneprocel benzamide antipsychotic benzamide class bexotegrast binding affinity biomarker testing biotech acquisition biotech merger biotechs branded drugs brensocatib calcium glucarate cancer care cancer drug development cardiometabolic disease care activity cell renal cell carcinoma centanafadine checkpoint inhibitors childhood vaccine schedule claims clinical pipeline clinical remission commercial strategy companion diagnostic compounding pharmacies constraints data integration data manipulation deadline deal degraders deucravacitinib digital pathology direct-to-consumer sales discount domestic manufacturing dosed dostarlimab draft guidance drug acquisition drug efficacy drug manufacturing drug shortages election epigenetic reprogramming exon federal funding federated learning fibroblast growth factor 21 first-line therapy gMG gepotidacin global expansion governance guidance cut headquarters health data healthtech iTeos ianalumab ifinatamab inhaled therapy interleukin-23 investor itepekimab language models liraglutide mRNA Vaccines meeting merger agreement mergers mid-stage trial milvexian mimetics nPulse nerandomilast net sales neurological diseases nex-z next-generation nivisnebart oHCM obesity trial obinutuzumab older onvansertib operating profit oral therapies oral treatment orexins ounce outcomes oveporexton pacibekitug partnership termination patented drugs patient death patient outcomes payment payments pemvidutide petrelintide pharmaceutical acquisition pharmaceutical partnership pipeline reduction pirfenidone platinum-resistant preclinical programs predictive models premium prepulse inhibition activity prescription drug costs priority review vouchers private placement psychedelic therapy public trust pumitamig reality refusal regorafenib regulatory filings regulatory guidance regulatory science research collaboration review extension rezpegaldesleukin ruxolitinib sacituzumab tirumotecan safety review scrutiny second-line treatment seed fund setmelanotide skepticism small molecule therapeutics specialty medicines statutory scheme stock drop stock plunge strategic partnership strategic partnerships strategic restructuring succession synergies terminations therapeutic areas therapeutic protein threat ticker travel trial design twice-yearly injection type 2 inflammation upsized vaccine overhaul vaccine schedule valproic acid glucuronide virtual care zasocitinib zumilokibart 100% 15% 200 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene 75% 8 AACR25 AAV Vector ABBV-295 ABI-5366 ACR gene ACTN4 wt Allele AERIFY-1 AERIFY-2 AFFINITY DUCHENNE AH 001 AI Platform AI drug design AI health AI platforms AI skills AI tool AI-native platform ALK Inhibitor AMD AMG AML ANCA vasculitis ANGPTL3 ANOPHTHALMIA AND PULMONARY HYPOPLASIA AOC AP306 APG777 APMD ASCVD ATG-201 ATTD ATTRv-PN AVLN Abeona Abnormality of mitochondrial metabolism Acadia Accelerated Approval Accurate (qualifier) Acromegaly Actinium Actuate Therapeutics Adaptimmune Administration of prophylactic statin Administrative action Adoption Adverse effects Advertising (activity) Adverum Biotechnologies Advisory Panel Age Aging AgomAb Agreement Alagille Syndrome Alameda Headquarters Alcohol Use Disorder Aldeyra Alexander Disease Alfasigma Allo-Glue platform Allogene Allogeneic Alvotech Alzheimer Alzheimer 's psychosis Amazona Ambulatory Care Facilities Amgen 's Amgen settlement Amicus Therapeutics Amitiza Amplia AnHorn Medicines Analgesics Analgesics, Non-Narcotic Anti-Inflammatory Agents Antibody Therapy Antimicrobial Resistance Antistreptolysin O Anxiety Disorders Appia Bio Apple Watch Apply Arbutus Arenaria <Aves> Arrowhead Arthritis, Psoriatic Arthrosi AsedaSciences Asia, Southeastern Atopic Attruby Aurinia Autoantibodies Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes Avadel Pharmaceuticals Availability of Aves AviadoBio Avlayah Axpaxli Ayrmid Azafaros B-cell depletion BCG-Unresponsive BGM0504 BIIB080 BIOSECURE BMN BMS BNC210 BPC 157 BPL-003 Bassas da India Batoclimab Baxfendy Bay Area Be6A Beam Therapeutics Becker Muscular Dystrophy Behavior Big Beautiful Bill Bill Anderson Bill Cassidy Bimzelx Bio-Rad BioAge BioArctic BioCapital BioNTech 's Biochemical Pathway Biological Availability Biopharma Advisory Board Biopharma Sentiment Index Biopharma layoffs Bioscience Biotech Innovation Black Box Warning Blackstone Blackstone Life Sciences Blackwell GPUs Blood Pressure Bloomington Indiana Bluebird Bio Boston Scientific Boundless Bio Brain-Computer Interfaces Breakout Ventures Brepocitinib BrightGene Broad Institute Bronchiectasis Bruton 's tyrosine kinase inhibitor Buyout CALD CAN-2409 CD19xCD3 CD388 CE (Rh group) CELIA CELMoD CGM CHF CLL-313 CLL-322 CLN-978 CMPX COMPANION-002 CORALreef CORALreef AddOn COVID-19 Vaccines CPOX gene CRL CROI CRSwNP CSU CT-996 CTSC gene CUTX-101 Cadence OTC Calquence Cancer Detection Candel Therapeutics Candidiasis, Chronic Mucocutaneous Capacity Capillary Leak Syndrome Capital Partners Caplyta Capricor Deramiocel Cardamyst Cardiovascular Risk Cartesian Cartography Biosciences Case (situation) Cash Crunch Catalent Catalent Indiana Cataplexy Cavazzoni Celea Therapeutics Celiac Disease Cell Engineering CellCentric Cellares Celltrion Center for Drug Evaluation Centers for Medicare & Medicaid Services Central Core Myopathy (disorder) Cerebral Edema Chai Discovery Chairperson Challenge Chancery Charles River Laboratories Chickenpox Chief Business Officer Chief Product Officer Chief Technology Officer Chimeric Antigen Receptor T-Cell Therapy China-based Chinese biotech Cholestasis-edema syndrome, Norwegian type Cholestatic pruritus Chorionic Villi Sampling Chris Boerner Chris Klomp Christophe Weber Chronic cough Chronic inflammatory disorder Chronic low back pain Chronic neutropenia Chronic sinusitis Cidara Therapeutics City of Boston Cityblock Health Clarity Claude ClearNote Health Clinical Advisory Board Clinical Benefit Clinical Decision Support Clinical Oncology Clinical Services Clinical action Closed Cogent Biosciences Colorado Columvi Commercial Managed Care - Pharmacy Benefit Manager Commission approval Commissioner 's National Priority Voucher Communication Communications Media Community Company Split Comparative Efficacy Comparison Compass Therapeutics Compounders Comprehensive Conferences Consultation Consumer Safety Continuous Glucose Monitoring System Continuous glucose monitoring Contract Research Organization Corcept Corcept Therapeutics Cosentyx Cost Savings Country Covid vaccine Crohn 's & Colitis Congress Crystalys Therapeutics Cullinan Customer Cutaneous DB-OTO DEI DEL-AI DELIVER (veterinary product) DMPK gene DNA Replication DNA medicines DOJ DOR/ISL DT120 ODT DTC Daily Dapiglutide Darovasertib Darzalex Faspro Data Analysis Data Integrity Data Quality Data Safety Daytime Somnolence Deep Apple DeepHealth Deerfield Management Definium Therapeutics Degenerative polyarthritis Degrader Delaware Delaware Court Deloitte report Dental Plaque Dentatorubral-Pallidoluysian Atrophy Depression Depression, Bipolar Depression, Postpartum Deramiocel Dermatitis Dermatologic disorders Dermatology field Dermatomyositis Diagnostic Imaging Disease remission Donald Trump Donanemab Dopaminergic Neurons Dordaviprone Dr. Droughts Drug Approval Process Drug Costs Drug Design Drug Enforcement Administration Drug Formulation Process Dry Eye Syndromes Duke Clinical Research Institute Dwarfism EASI EASI-75 EIK1005 EMA EMBARK trial EMMI EPI-321 ESMO Congress EU Approval EV-304 EZH2 protein, human Economics Electroencephalography Electrophysiology (science) Elicio Therapeutics Eligibility Determination Elivaldogene autotemcel Elon Elraglusib Emergency Contraception Employment Termination Encephalitis, St. Louis Endo England Enhance (action) Entrada Enveda Environment Enzymes Epcoritamab Epigenomics Erythrocytes Escena Escherichia coli Esperion Etavopivat Evaluation procedure Evernorth Evidenced Evotec Excessive (qualifier value) Exdensur Executive Chairman Eye FIBRONEER-ILD FLAURA2 trial FY2025 Fabhalta Factor XI Factor XIa inhibitor Fair Language Proficiency False Claims Act Familial mitral valve prolapse Fast Track designation FcRn Federal Circuit Feedback - system communication Fertility Agents Fertilization in Vitro Fibrodysplasia Ossificans Progressiva Fibromyalgia Fibrous histiocytoma of tendon sheath Financial Forecast Revision Flatulence Focal Food Safety Force Fortress Forzinity Foster City Fosun Pharma Fragile X Syndrome Fraud Frazier Life Sciences Friday Friedreich 's ataxia Fujifilm Futility GABA Modulators GEP-NETs GLP-1/GLP-2 GLP-1/glucagon GS-1720 GS-4182 Gaithersburg Garijo Gastrointestinal Stromal Tumors Gazyva Gemini of Coiled Bodies Gender Gene Expression Gene Mutation Generic Competition Genetic Medicine Genetic Profile Genrix Bio George Tidmarsh Goldcrest Goldman Sachs Gonorrhea GoodRx Google Cloud Govorestat Grail Gram-negative bacteria Guidelines HARMONi trial HELP Committee HER2-mutant HER2-positive HER2-positive carcinoma of breast HFpEF HIBISCUS trial HIV sales HKEX HLX316 HOPE-3 trial HR+ HRS-5346 HYMPAVZI Haisco Hallopeau-Siemens Disease Hand Strength Hansoh Pharma Harbour BioMed Hazard Ratio Health Care Market Health Personnel Health agencies Healthcare AI Heart Helicon peptide platform Hematology (discipline) Hemlibra Hemophilia A Hengrui Pharmaceuticals Hepatitis D Infection Hereditary Hereditary Coproporphyria Hernexeos Herpes zoster disease High High-Throughput Nucleotide Sequencing Highest Hikma Pharmaceuticals Hillhouse Investment Management Home environment Hong Kong IPO Hong Kong NDA Hospitalization Hospitals House mice Hua Medicine Humira Hyderabad Hyperlipidemia Hypoimmune Technology Hypoparathyroidism I-DXd IBI343 ICOTYDE IDeate-Lung02 IGFBP7 gene IGNYTE IGNYTE trial II IMNM IMVT-1402 IQVIA ITM-11 IZERVAY Iambic Therapeutics Ibex Medical Analytics Ibrance Ideaya Biosciences Idorsia IgG4-Related Disease Illinois (geographic location) Imaavy Imbruvica Immune System Diseases Immune Tolerance Immune response ImmuneOnco Immuneering Immunization Schedule Immunoglobulin IgG4 Immunology pipeline Immunoregulation Impaired cognition Imunon Inavolisib Increased Independence Individual Adjustment Infantile Neuroaxonal Dystrophy Infinimmune Infusion procedures Ingram Inobrodib Insitro Inspection (procedure) Intact Intellectual Property Intelligence Interim International Interval Intra-Cellular Therapies Invasive Invasive meningococcal disease Inventiva Investigational New Drugs Investor Reaction Io satellite Ionis Isomorphous Israeli (population group) Itovebi J&J 's JCR JNJ-4496 Janssen Japanese language Jascayd Jay Jay Bhattacharya Jeito Capital Johns Jon Congleton Jorna Judge KEYNOTE-B15 KGaA KOL Bulletin KOMET-001 KRP KRP-M223 KRRO-110 KRSA-028 KRYSTAL-1 KT-621 KYV-101 Kai Beckmann KalVista Kartos Therapeutics Karyopharm Therapeutics Kennedy Kerendia Kevin Tang Kezar Life Sciences Kidney Failure, Acute King Kisqali Kissei Korro Bio Korsana Biosciences Kresladi Kura Oncology Kyle Diamantas Kymab Kyorin Kyowa Kirin Kyverna LAVA LB2501 LBCL LBRX LEAP LGBTQ+ LUMRYZ LYT 100 Languages Lars Fruergaard Jørgensen Late stage Latozinemab Laurie Stelzer Lawyer (occupation) Lazcluze Leadership Transition Lean Mass Leukocyte adhesion deficiency type 1 LifeMD Lifting Lightning Step Lila Sciences Lilly Gateway Labs Lilly TuneLab Lilly collaboration Lilly partnership Limited (extensiveness) Linerixibat Lipid Nanoparticles London Long Intergenic Non-Protein Coding RNA Lonza Lumakras Lung-01 Lunsumio Lupus Erythematosus, Cutaneous Lyme Disease Lysergic Acid Diethylamide M&A surge MADRS score MAGNITUDE trial MASP-3 Inhibitor MBX Biosciences MCED MEK MEMO1 gene MET-233i MIBC MPLT MRGPRX2 gene MRT-6160 MSTAR MYOTONIC DYSTROPHY 1 Mabwell Major Depressive Disorder Malignant neoplasm of anus Mallinckrodt Management procedure MannKind Mantle cell lymphoma MariTide Massachusetts (geographic location) Measures Mechanism Framework MedKey Median Technologies Mehmet Mendra Meningococcal vaccine Mental Recall Mesenchymal Stem Cells Metabolic Syndrome X Metastasis from malignant neoplasm of colon and/or rectum Metastatic Pancreatic Ductal Adenocarcinoma Mexico Microbicides Microbiome Microglia Microsoft Mike Doustdar Milestone Miller Dieker syndrome Mineralys Mismatch Repair Deficiency ModeX Molecular Glue Degrader Monte Rosa Therapeutics Montgomery-Åsberg Depression Rating Scale Monthly (qualifier value) Morning After Pill Mother (person) Mozafancogene Autotemcel Mucopolysaccharidosis Type IIIA Multiple Sulfatase Deficiency Disease Musk secretion from Musk Deer Mycoses Myeloid cell engager Myotonic Dystrophy Myqorzo NALF2 gene NBD1 NDSRI NEFL gene NEJM NEREUS NPM1 Nasdaq EIKN Nasdaq PBLS Nasopharyngeal carcinoma National Priority Voucher Navsunli NervGen Pharma Neurimmune Neurodegeneration Due To Cerebral Folate Transport Deficiency Neuroendocrine Tumors Neurofibromatosis 1 Neurostimulation procedures of spinal cord tissue New Approach Methods New-onset refractory status epilepticus NewAmsterdam Pharma NewCo NewLimit Newleos Nimbus Therapeutics Note (document) Novo Novo Nordisk Foundation OBBBA OPKO Health OTOF gene OXTR gene Obesity care ObesityWeek 2025 Obexelimab Obicetrapib Obstetric Delivery Obstructed Ocrevus Ocular Toxicity Office Ohtuvayre OliX Ollin Ollin Biosciences Omeros Oncologic Drugs Advisory Committee Oncology drugs Opdualag Open OpenFold Consortium OpenFold3 Opinions Optogenetics OrbiMed Orca Bio Orexin Receptor Agonist Organization administrative structures Organon Orionis Biosciences Ornithine carbamoyltransferase deficiency Orthopedics Ouro Medicines Overweight Oxnimbi PCAC PD-1/VEGF bispecific antibody PD-L1-positive PD-L1xVEGF PF-08653944 PHD1/2 inhibitor PIK3CA mutation PLK1 gene PLN-101095 PLRX PM359 PP405 PROBODY PROTEUS trial PTC518 PWS Pancreatitis, Acute Papzimeos Paragon Therapeutics Parkinson Disease Paroxysmal nocturnal hemoglobinuria Paroxysmal supraventricular tachycardia Partial Parts per million (qualifier value) Patent extension PathAI Paul Offit Paulo Fontoura Penmenvy Pericardial effusion Personalized cancer care Persons Pet Animal Petosemtamab Phage Therapy Pharma AI Pharmaceutical Research Phase 1/2a Phase 2a trial Phase II B Trial Phase IIa Philadelphia Philips Phobia, Social Physical and emotional exhaustion state Pick Disease of the Brain Pierre Fabre Pipeline Progress Pivot Device Plexiform Pliant Therapeutics Pluvicto Podnosis Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Poolbeg Positive Post-transplant lymphoproliferative disorder Postpartum Precigen Prediabetes syndrome Predictive analytics Pregnant Women Presentation Preventive Care Previous Primary Health Care Primary Hypersomnia Primary amyloidosis Prime Medicine Principles Priovant ProfoundBio Progranulins Project NextGen Promotion (action) Protection Protein Degradation Protein Engineering Protein Tyrosine Kinase Proteins Protocols documentation Prussia Public Preparedness Pulmonary Pulmonary Hypertension Q1 2025 QIAGEN Quality of life Qyuns Therapeutics R1 Therapeutics RAS inhibitors RC148 RECONNECT RGX-111 RNAi medicines RP-A501 RSV RTW RadNet Radiant heater Records Recruitment Recurrence Recursion Pharmaceuticals Relapse Relocation of home or business Report (document) Republican Republicans Response Letters Retevmo Retinal Vein Occlusion Rett Syndrome Reunion Revenue Upgrade Revtorpyk Rezdiffra Rezpegaldesleukin Rhapsido Rigel Pharmaceuticals Rilzabrutinib Rising Risk Management River Laboratories Robert Langer Rogaine Romvimza Rybelsus Rytelo SA030 SABCS SAT-3247 SCTX SENS-601 SERENA-6 trial SG&A SIMTRIYO SK Biopharmaceuticals SLL SOLSTICE SOPHiA GENETICS SPN-820 SPS STAR-221 STARGLO STAT6 degrader SV Health Investors SVP SYMPHONY-1 trial Sail Biomedicines Salts Samsung Sanofi Ventures Saphnelo Sarcoidosis Satellos Scancell Scemblix Schrödinger Scientific Study Scott Gottlieb Seagen Seaport Therapeutics Sebetralstat Selective Estrogen Receptor Down Regulator Self Confidence Senate Finance Committee Sense of identity (observable entity) Sentynl Therapeutics Septerna Serapha Bio Sernova Serplulimab Services Shockwave Medical Short Bowel Syndrome Sidewinder Therapeutics SigVie-002 Simcere Singapore Sino Biopharmaceutical Sionna Site SkySTAR platform Skyhawk Skysona Sleep Sleep Apnea, Obstructive Sleep Disorders Sleeplessness Sobi Social Welfare Social stigmata Sodium Channel Blockers Software as a Medical Device Soleno Spero Therapeutics Spinout St. Louis Standard (qualifier) Standard BioTools Star Therapeutics Stargardt's disease Steroids Stewardship Stiff-Person Syndrome Stivarga Stock Crash Stock exchange Stoke Therapeutics Subcutaneous Keytruda Summer Sun Pharma Sunwave Super Bowl ad Sustained-release Mitomycin C Hydrogel Formulation UGN-102 Suzetrigine Svalbard Switzerland Symbravo Synlogic Synthetic Biology Synthetic Lethality Syringes TAK-861 TALAPRO-2 TAR 200 TB-500 TCE TERN-601 TNFRSF4 gene TP53 gene TPTE2 gene TRANSCRIPTION FACTOR TSND-201 TSRA-196 TTR wt Allele TUB-030 Tabelecleucel Taiho Tango Therapeutics Targeted Protein Degradation Targeted Therapy Tazverik Tecartus Tecelra Tecvayli Teladoc Telix Tempus AI Tenaya Therapeutics Tender Tension Tepezza Terray Therapeutics Texas Thalassemia Theranostics Theravance Biopharma Thrive TimeLine Fluoride Releasing Resin Tissue damage Transaction Transcend Therapeutics Translarna Treating Treatment Protocols Treeline Tremfya Trontinemab Trulicity Trump drug pricing Trump loyalists Trump vaccine schedule Tuberculosis TuneLab Type 2 Tyruko Tysabri U.S.-China UAE UBT251 UGX-202 US tariffs USPSTF Union United States Health Resources and Services Administration United Therapeutics Universities University of Pittsburgh Unnatural Products Unsolicited Adverse Event Utah VANQUISH-1 VESALIUS-CV VESPER-3 VGA039 VIKTORIA-1 VTCN1 gene Vaccine Development Vaccines, Combined Valo Health Variant Varseta-M Vascular Diseases Ventus Therapeutics Veppanu Vera Therapeutics Verona Pharma Verzenio Viable View View Bora Vigil Vimkunya Vir Biotechnology Vital capacity test Vomiting Voxzogo Vykat Vykat XR Vyndamax WEE1 gene WVE-006 Wainua Wakefulness Walmart Pharmacy Wayrilz Wellcovorin Workforce - population group Wugen XLRP Xocova Xolair Xpovio YB-101 YUVIWEL Yale Yescarta YolTech Ypsomed Yupelri ZEVASKYN ZYCUBO Zag Bio Zai Lab Zaltenibart Zegfrovy Zepzelca Ziihera Zilganersen Zimmer Biomet Zydus Lifesciences Zynyz access program acute liver injury acute pain treatment ad campaign adagrasib adulteration advanced breast cancer advanced solid tumors agentic AI algorithm all-stock alpha therapies alpha-Synuclein amisulpride ampreloxetine amycretin anti-IgE anti-TL1A anti-TSHR antibody anti-seizure medication anti-tumor activity antiarrhythmic peptide antibody libraries antitrust lawsuit apatinib apitegromab appeal at-home treatment at-risk atebimetinib avacincaptad belrestotug benzamide bevacizumab bexobrutideg bezuclastinib bile duct syndrome biopharma executives biopharmaceutical development biopharmaceutical industry biopharmaceutical manufacturing bioprocessing biotech closures biotech downturn biotech partnership biotech startup bispecific ADCs bispecifics black box blockbuster drugs blood thinner board chair bone health bota-vec boxed bretisilocin brexpiprazole briquilimab business development buyback campus cancellation cancer discovery cancer pipeline capitalization capsule (pharmacologic) carbetocin cardiometabolic health cardiovascular pipeline cell line development cell therapy manufacturing central venous catheter (CVC) sets cetuximab charge amounts checkpoint inhibitor cholesterol chronic hand eczema cibotercept civorebrutinib claseprubart class action clinical AI clinical operations clinical outcomes clinical program clinical strategy clinical trial design clinical trial termination clinical-stage clinical-stage assets cold chain logistics competitiveness concept continuous glucose monitor contract manufacturing corporate strategy cost management cost-cutting measures ctDNA danuglipron darlifarnib day dazucorilant de novo design debt decentralized decision delay decitabine denosumab departures dexamethasone diabetes care diabetes drug direct-to-patient disease prevention disease treatments disruption divestment dividend domestic drug manufacturing domestic partnerships dorzagliatin dotinurad drug applications drug development halt drug launches drug rejection drug response drug spending drug-resistant epilepsy dry AMD dual-targeting CAR-T dupilumab durability early development economic impact elecoglipron engine entry - ActRelationshipCheckpoint envudeucitinib etripamil exacerbations executive appointment executive promotions executive transition executives exemptions expert experts eyonis fast-track approval felzartamab fentanyl crisis fill-finish financial performance firings first-in-class first-in-human framework functional cure gains gastroesophageal adenocarcinoma gemcitabine gene targets generic pharmaceuticals glucagon glucokinase activator goal growth outlook growth strategy hair regrowth health disparity healthcare investment heart health hemoglobin response high-risk groups high-throughput screening human antibody human papillomavirus hydrocortisone iRhythm iberdomide ibogaine icotrokinra impairment charges import alert improvements incretin drugs inebilizumab infigratinib infringement injunction interim investors islatravir islet isononanoyl oxybenzene sulfonate issues leader leadership appointments leadership shakeup leases leucovorin lexicon listings liver transaminase liver-targeted RNAi lobbying loncastuximab tesirine long-acting lonvo-z lorigerlimab losses low-grade mCRC mRNA cancer mRNA therapies macrocyclic peptides maintenance trial manufacturers manufacturing capacity manufacturing deficiencies masetecan mass layoffs medical AI medical technology melanoma drug meloxicam methodologies military companies mirdametinib mitomycin mo-rez mocertatug molecular glue degraders molecular glues multimodal AI multispecific antibodies namilumab nanoparticle delivery narmafotinib navepegritide net income next-generation biologics next-generation sequencing nomination non-opioid pain drugs on-body injector once-monthly operational ophthalmic preparation oral drug oral obesity drugs oral peptides oral small molecule oral therapy p300/CBP inhibitor patent cliffs patient safety pegcetacoplan pegol pegozafermin persevERA personal reasons personalized cancer pharma innovation pharma partnerships pharma revenue pharmaceutical competition pharmaceutical litigation pharmaceutical manufacturers pharmaceutical negotiations pharmaceutical partnerships pharmaceutical regulation pipeline cutbacks pipeline focus pipeline pivot pipeline prioritization pipeline review pituitary adenylate cyclase activating polypeptide placebo-controlled trials platform technology designation point-of-care portfolio strategy povorcitinib precision cancer preclinical pipeline predictive presbyopia prescription discounts price cut prime editing probationary workers product profit guidance protein design protein design AI protocol design quality management questions ranibizumab real-time monitoring rebound recipients recombinase reconciliation recurrence prevention reforms registrational development regulatory challenges regulatory decisions regulatory environment regulatory filing regulatory hurdles regulatory policy regulatory review regulatory setback regulatory strategy relacorilant removal technique repeal reproductive healthcare reproxalap requirements research funding reshuffle resilience rezetecan ribupatide risk mitigation risk-benefit analysis rizatriptan sac-TMT sales growth search - EntityNameUse sertraline setback sevabertinib sigvotatug vedotin site closures skinny label small molecule therapy solbinsiran sotorasib sparsentan speed spindle orientation checkpoint stake startups stop work strategic brands strategic realignment subcutaneous delivery subcutaneous formulation subscription program survodutide sustainability systemic treatment tafamidis takeover taletrectinib tariff exemption tazemetostat tebapivat tenosynovial therapeutic antibodies thimerosal third quarter 2025 tividenofusp topline tourmaline tovecimig treatment failure treprostinil palmitil inhalation powder trial failure trispecific antibody troriluzole tulisokibart tumor targeting tumor-activated tumor-selective antigens ultra-rare diseases underwriters underwritten ustekinumab uveal melanoma vaccine access vaccine deaths vaccine developers vaccine panel vaccine politics vaccine sales varsetatug vasomotor symptom vatiquinone velinotamig vepdegestrant vera vomiting prevention vormatrigine vosoritide voucher program warning letters webinar weight-loss weight-loss pill wet AMD wet age-related macular degeneration wild-type winners working capital wound care xRNA zimberelimab zimislecel (3beta * * European Life Sciences Coalition * * Global Expansion * * * * Riad Mishlawi * * * * Vivek Ramaswamy * * * * atopic diseases * * * * functional cell 0% 10 mg 15B 1964 1L pancreatic cancer 2-aminoethylmethyl sulfone 20% 2024 2026-2035 2032 22C3 24-Hour Data 28.7% 3 serotype 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one 30% 35 36% 4D Molecular Therapeutics ' 5,6-methylenedioxy-2-aminoindane 50–59 52-week results 55% 5B 5alpha)-isomer 6-amino-1-hydroxyhexane-1,1-diphosphonate 7.5 mg 8(a 8.875% 80% 90% 95% A&B/SARS-CoV-2 AA Signature AAAAI AACR-NCI-EORTC AAD AAER AAIC AAPS NBC 2026 AARD gene AARP AAV antibodies AAV gene therapy AAV-AIPL4 AAV-based gene therapy AAVB-081 AAVantgarde AAVrh74 AAVrh74 vector AB-1005 AB-2100 AB001 ABCA4 gene ABI-4334 ABP-102 ABPI ABS-0871 ABS-1230 ABTECT ABTECT-1 ABTECT-2 ABX464 ACCENT trial ACCESS II ACHIEVE-1 ACI-7104.056 ACP-101 ACR-2316 ACR50 ACTH receptor antagonist ACUA AChR-Ab ADA25 ADAM11 protein, human ADAMTS-5 ADAPT-PD study ADARx ADEL ADEPT ADEPT-2 trial ADMET ADPD ADVC001 AFFINITY DUCHENNE trial AFFIRM-1 AFFIRM-1 phase 3 trial AFPs AGCM Biogen investigation Stratify test AGIO AGXT gene AHA AI Assist AI Factories AI Proteins AI Stethoscope AI agents AI antibiotic discovery AI automation AI biomarker AI biopharma AI clinical trials AI collaboration AI doctor AI foundation model AI guardrails AI health app AI healthtech IPOs AI humanoid robots AI imaging AI lab AI lung cancer AI molecule models AI oncology imaging AI refills AI safety AI scientist AI solutions AI supercomputer AI therapeutics AI token AI tools AI ultrasound AI workflows AI-Based Protein Design AI-Powered Test AI-based AI-based drug discovery AI-designed AI-designed drugs AI-designed molecules AI-designed pill AI-discovered drugs AI-driven antibody AI-engineered antibody AI-generated AI-guided AI-powered credentialing AI-powered diagnostics AI-powered drug discovery AI-powered healthcare AI-powered solutions AI-ready AI/ML-enabled product AIDS Healthcare Foundation AIM-MASH AIR-001 AJ1 AK006 AK0406 AKAP9 protein AKAP9 protein, human AKT inhibitors AKY-1189 AL ALK7 ALKOVE-1 trial ALNY ALPHA3 ALPHA3 trial ALT-positive ALTO-101 ALTO-203 ALX ALX2004 ALZ-801 AMA AMGN AMONDYS AMP KRAS Vaccine ELI-002 AMPA receptor modulator AMPA-PAM AMPLIFY-7P trial AMT-191 AMWC AMX0035 AN2 ANDA ANNE ANX005 AP3 APG-5918 APIs APJ APLAS APOE program APOL1-mediated kidney disease APRIL inhibitor AQUILA study AR navigation ARC-EX System ARCT-032 ARD-201 ARG-007 ARIA ARIA risk ARIA-E ARID1A mutation ARO-ALK7 ARO-APOC3 ARO-C3 ARO-INHBE ARO-PNPLA3 ARO-SNCA ARPA-H ARPA-H THRIVE ARPA-H grant ARROS-1 trial ARTBIO ARTEMIS-008 ARTV ASC41 ASCEND trial ASCENT ASCO GI 2026 ASCO preview ASCO-GU ASCO25 ASMB ASPIRO trial ASPR ASRS ASTX029 ATG-022 ATG-125 ATG-207 ATI ATLAS-UC ATMP regulation China ATN ATNM-400 ATR ATR/mTOR Inhibitors ATSN-101 ATSN-201 ATTAIN-2 ATTO-1310 ATX01 AURKA inhibitor AURN001 AVB-114 AVD-104 AVTX AVZO AWS HealthLake AXS-14 AZD0120 AZD0780 AZD5004 AZSTARYS AZUR-1 AbCellera AbForge ® platform Abata AbbVie CEO AbbVie New Jersey AbbVie Robert Michael Abbas Kazimi Abbisko Cayman Abbisko Therapeutics Abbreviated New Drug Application Abcam Abdominal Fat Abe Bassan Abecma AbelZeta Abeona 's Abetalipoproteinemia Abivax falls Abivax stock Absci Academia (organization) Academy of Pediatrics Accelerate Diagnostics Accelerate Growth " programme Accord BioPharma Accrual Accuray Achieve Life Sciences Acne Vulgaris Acoramidis Acquired Immunodeficiency Syndrome Acrivon Acrobat Genomics Act of Documentation Actimab-A Acting Actinium Pharmaceuticals Actio Actithera Active Activin E :* * Actuate AcuCort Acute leukemia Adagene Adaptive Biotechnologies Adaptyv Bio Adcetris Adcomm Addictive Behavior Adenomatous Polyposis Coli Adenosine deaminase deficiency Adenovirus Infections Adherence (attribute) Adherence To Medication Regime Aditum Adjunctive Orthodontic Procedure Adjuvant Melanoma Admilparant Adolescence AdvaMed Diabetes Sector Advanced Imaging Suite Advanced Manufacturing Technology Advanced Therapy Medicinal Products Advanced Urothelial Carcinoma Adverse reaction to drug Advisory Board Advita Ortho Aerska Afami-cel Afimetoran Africa Afya Limited Agenesis of corpus callosum Agentic Harmonization Assistant Agenus Aggressive Aggressive Periodontitis Agilent Agitation Ahmed ElNawawi AiTEM AilsynBio AimedBio Ainnocence Airna Ajax Health Ajax Therapeutics Ajay Nirula Ajovy Akeega Akeso 's Al-powered Alamar Biosciences Alan Ashworth Alan Bash Alan Sandler Alarm device Albert Bourla Alberto Lopez Toledo Albireo Portfolio Alchemab Alcohol abuse Alcohol dependence scale Alcohol or Other Drugs use Aldose Reductase Inhibitor Alejandro Weinstein Alembic Pharmaceuticals Alexei Algen Biotechnologies AlgoTx Alkeus Allakos Allergan Allergy Specialty Allergy to peanuts Allison Candido Allogeneic Anti-CD19 1XX-CAR T-cells FT819 Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019 Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010 Allogeneic Human Stem Cell-derived Pancreatic Islet Cells VX-880 Allogeneic bone graft Alloimmune thrombocytopenia Allumia Ventures Alluminox Alma AlphaDirect technology AlphaFold AlphaLab AlphaMedix Alphabet Altanine Altasciences Alteogen Alternative Funding Programs Altman Alto Neurosciences Altuviiio Alumni Alva Therapeutics Alveltamig Alyftrek AlzeCure Alzey investment cut Alzheimer 's agitation Alzheimer 's disease psychosis Alzheimer 's treatment Alzheimer's Disease AmBisome Amar Thyagarajan Amarin Amarin Pharma Amazon Health Amazon Pharmacy Amazon Web Services AmbioPharm Ambros Therapeutics Ambrosia Ambrosia Biosciences Ambrx American Cancer Society American College of Cardiology American Depositary Receipts American Epilepsy Society 2025 AmericasMedicines.com Amethyst Amezosvatein Amgen Tepezza active Amgen Uplizna Amit Singal Ammonia level finding Amneal Amolyt Amondys Amphastar Amplify trial Amsterdam facility Amtagvi Amylin Candidate Amyloid-targeting therapy Amylyx AnTenGager Anabolism Analog Analysis of substances Anaphylm Anatol Andembry Andreas Goutopoulos Andreas Wallnöfer Andreessen Horowitz Andrew Grethlein Andrew O Andrew Witty Androgen-Insensitivity Syndrome Andy Thomas Anesthesia procedures Ang2 Angela Breton Angelini Industries Angelman Syndrome Angiotensinogen Anima Biotech Animal Health Animal Testing Animal Welfare Animal mane Anixa Ankylosing spondylitis Ankyra Therapeutics Ann Arbor Anne Anne Wojcicki Annexon Anniko Annual Reports Anomaly Ventures Anovo Ansa Ansa Biotechnologies Anselamimab Ant Afu Ant Group Antares Antares Therapeutics Anterior Anthos Anthropological Culture Anti-BTN3A Agonistic Monoclonal Antibody ICT01 Anti-CD19 Monoclonal Antibody Anti-CD36 mAb Anti-CD47 Monoclonal Antibody AK117 Anti-CD52 Monoclonal Antibody ALLO-647 Anti-Claudin18.2 ADC CMG901 Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 Anti-Kickback Statute ( Anti-OX40 Hexavalent Agonist Antibody INBRX-106 Antiandrogen therapy Antibiotic Resistance Antibiotic Resistance, Microbial Antibiotic therapy Antibody Solutions Antibody Therapeutics Antidepressive Agents Antifungal Agents Antineutrophil Cytoplasmic Antibodies Antitrust Probe Anumana Anxiety Anything Anzupgo Apheris ADMET Network Apis (invertebrate) Apnea Apollo robot Appeals court decision Apple App Store Apple Health Applied Pharma Apptronik Apretude Aquestive Therapeutics Aquipta Aqvesme Araris Arbitrating Arbuckle Arc Bio Arch Biopartners Arch of foot Archimed Architecture Arcturus Arcturus Therapeutics ' Arecaceae Arena BioWorks Areteia Arexvy Arginine Vasopressin-Neurophysin II Preproprotein Argo Biopharma Arikayce ArkBio Arrowhead RNAi Arrowhead plozasiran ArsenalBio Artera Arteriosclerosis Arthritis Artificial (qualifier value) Artificial cardiac pacemaker Artiva Biotherapeutics Asarina Ascenta Capital Ascentage Pharma Ascidian Therapeutics Ashiq Khan Asia-Pacific Asian Americans Asian Indian AskBio Aspect - Kind of quantity Aspen, Bach Flower Essence Assertio Assertio Holdings Assured Astellas Pharma Astex AstraZeneca 's AstraZeneca Truqap Faslodex Astria Astrin Biosciences AstroRx ® Atai Life Sciences Atara 's Atara Biotherapeutics Ataxia Telangiectasia Ataxia, Spinocerebellar Atea Athetoid cerebral palsy Athlone facility Atirmociclib Atropos Health Atsena Attack device Attention Attenuated by (contextual qualifier) Attovia Therapeutics Atumelnant Atypical Aubrey C. Galloway Audit Committee Chair Augmented Reality August 12 August 2028 August 2029 Aurion Biotech Autism Spectrum Quotient Autism trial Autofluorescence Autoimmune Alliance Autoimmune Chronic Hepatitis Autoimmune Therapies Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F Autolysosome Automate (invertebrate) Automated (qualifier value) Autonomous Healthcare Autonomous Research Auvelity Avacta Avadel Avadel acquisition Avalo Therapeutics Avantect Avantect ® Pancreatic Cancer Test Avastin Avenzo Avenzo Therapeutics Average Avicanna Avidity Avobis Bio Avoro Awards Awiqli Axelios sequencer Axial Axiom Biosciences Axplora Axsome Axsome Therapeutics' Ayvakit Azure A³ Strategy B Cell Llama B cell immunomodulator program B-Well trials B-cell Select ™ technology B7-H3-targeted sialidase B7H3/PTK7 bispecific TOP1 BAFF/APRIL inhibitor BAFF‑R BAG3-associated BATNA BBB BBB shuttle BBI-355 BBI-825 BBOT BBP-418 BCG Vaccine BCG-unresponsive BCL-2 Inhibitor [EPC] BCL11A gene BCL6 gene BCMAxCD19 BCR BDTX-4933 BEAM-302 BEHOLD-1 BEXMAB BGI BHB-1893 BHV-7000 BI BIC/LEN BII BINSA BIO board BL-B01D1 - 303 BLA BLSM BMB-101 BMB-105 BMRN BMS-986177 BMS-986322 BMS-Hengrui BNT211 BPI gene BPL BPSI BRCA BRCA2 gene BRENTUXIMAB BRIO I BRIO II BROADWAY BROADWAY trial BT-267 BT-409 BTK degrader BTKi BTN3A BW-20829 BX211 BXLS VI BYD Baby KJ Bacillus cereus Bacterial Endocarditis Bacterial Infections Baebies Baker Balinese language Bambusa Therapeutics Bangalore plant Barakat syndrome Barbara Barinthus Barrow Neurological Institute Barzolvolimab Basketball game Basking Ridge Bausch + Lomb Bausch Health Beacon Beat Becker Hewes Beeline Beginning Behcet Syndrome Belite Bio Belén Belén Garijo Bench International Benedikt von Braunmuehl Bepirovirsen Bepranemab Beqalzi Beqvez BerGenBio merger Berkeley Berkeley Vincent BetterHelp Bettis Bharat BiLockCatcher Bial Bias (Epidemiology) Bicara Therapeutics Bicillin L-A Bicycle Bicycle Health Bicycle Therapeutics Big Data Big Pharma investors Biliary Atresia Bilirubin Bill Adams Billion Collaboration Billioux Binding action Bintrafusp alfa Bio + Health Bio-Informatics Bio-Thera BioAtla BioCity BioClec BioCryst BioGPU BioLife Solutions BioPorto BioSpace BioStem BioVU BioVie BioXcel Therapeutics Biochemistry Biocodex Biocon Biologics Bioconjugation Platform Biocytogen Biodexa Bioeconomy Bioepis Biogen CEO Biogen Tysabri Sandoz Biohaven troriluzole Bioliberty Biological Response Modifier Therapy BiomX Biomanufacturing Strategy Biomedicine Biomolecular AI Bionyra Pharma Biopharm Biopharma AI CRM Biopharma regulatory issues Biopharma trade war Biopharmaceuticals Biosafety Bioshield Biotech Competition Biotech Fundraising Biotech Layoff Tracker Biotech pipeline shift Biotechnology Advantage Biotechnology perspective article Bipartisan Senate bill Bipartisan Support Bipolar I disorder Bitopertin Bivamelagon Bizengri Blackwell Ultra GPU Bladder Risk Blastic plasmacytoid dendritic cell neoplasm Blepharitis Blighia sapida Blinded Blood Blood Pressure Insights Blood Transfusion Blood coagulation tests BlossomHill Therapeutics IPO Blue Owl Healthcare Blueprint Medicines Board Directors Board Resignation Board change Boards (medical device) Bobby Hunter Body Composition Boehringer Ingelheim Germany Boltz-1 Boltz-2 Bone Density Bone Diseases Boost Boston Children 's Hospital Boston Pharmaceuticals Boston event Boundless Brain Brain Delivery Module Brain Implants Brain Injuries Brain Research Brain hemorrhage Brain stimulation Brain-Penetrant Drug BrainSpace BrainTransporter platform BrainTransporter technology Brainomix Brainomix 360 Brainshuttle Braveheart Bio Breakthrough Device Designation Breast Acoustic CT Brendan Doran Brenig Therapeutics Brexit impact Breye Therapeutics ' Brian Armstrong Brian Cherry Brian McKelligon Brian Thomas BridGene BridgeBio Pharmaceuticals Briggs Morrison Bright Minds Biosciences Brilaroxazine Brilliance Studies Bristol-Myers Squibb British Neuro-Oncology Society BroADen Phase 1b trial Bruce D. Forrest Bruin-CLL-314 Bruker Corporation Bruton's Tyrosine Kinase Inhibitors [MoA] Bullous pemphigoid BurstDR Business Update Call Bylvay Bysanti C-CAR031 C-reactive protein C-suite C-suite changes C1QA gene C3 G C3 complement inhibitor C3 glomerulopathy C4 Therapeutics C5 inhibitor CAB CABA-201 CADENCE study CADe/CADx CADx CAH CALM-1 CALM-2 CALR gene CAMP4 CAN10 CAP-002 CAPItello-280 CAPS-5 CAR T-cell CAR-T clinical trial CAR-T engineering CAR-iNKT cells CARDINAL study CARDIO-TTRansform trial CARIS Life Sciences CARsgen Therapeutics CB1 inhibitor CBB-120 CBC Group CBER CDER orphan drugs CBI-1214 CBX-250 CBX-663 CD CD19/CD20 CD20 Antigens CD20-directed therapy CD3 T cell CD38 Antigen CD38-directed antibody CD4 + T-cell CD4 + T-cells CD47 Antigen CD8 T cells CDC vaccine recommendation CDC7 protein, human CDH17 protein, human CDH6 gene CDK inhibitors CDK2/4 degrader CDK4 inhibitor CDK4/6 inhibitors CDMO platform CDMO/CRO CDMOs CDOO CDR-SB CDTO CE-IVD CEDAR study CELC CELIA Phase 2 trial CEO Kai Beckmann CEO Luke CEO Mike CEO Thomas Schinecker CEO Ulf Hannelius CEO Vas Narasimhan CEO appointments CEO replacement CEO resignation CEPI CETP CFD-FOLR1 CFIUS CHARM Therapeutics CHEK1 protein, human CHORD trial CHRS CHW Access Act CIAS CIDP CAPTIVATE trial CIHR CIRM CITY-FXI CITY-RBP4 CLD-423 CLIA CLIA-waiver CLL-314 CLL/SLL CLUS CMO appointment CMS CMS Interoperability Framework CMT-SORD CNS activity CNS drug development CNS pipeline CNS-3D CNS-penetrant COINS Act COM503 COM701 COMP005 COMP006 COMPOSE trial COO CORALreef Lipids CORALreef trial CORALreef trials CORDStrom CPI-refractory tumors CPO CR-001 CRB-701 CRBN gene CRC test CREM gene CRISPR CRISPR gene editing CRISPR therapies CRISPR therapy CROSSJECT CROs CRPS-1 CSB-001 CSL-Behring CSNK1E gene CSP2026 CT-132 CT-155 CT-388 CT-868 CT-P72 CTAD CTMS CTMX CTNNA2 gene CTPS1 inhibitor CTX310 CUE-501 CV features CX-2051 CXCR4 gene CYPRESS study Cabaletta Cabaletta Bio Cabometyx CagriSema Wegovy Calcified (qualifier) Calico Califf California residents Calley Means Calypso study Cambridge Massachusetts Cambridge R&D headquarters Cambridge research labs Camilla Harder Hartvig Camilla Sylvest Camurus Canadian Canadian Cancer Society Canal Row Advisors Cancer Diagnosis Cancer Drug Sales Cancer Drugs Fund Cancer Prevention Cancer Research Institute Cancer Risk Cancer Survival Candel Candid Therapeutics Cannes Cantargia Cantor CapVest Partners Capability Capital Expenditures Capital Markets Capitol Hill Capricor Caps Capsida Biotherapeutics Captain T Cell Carbapenems CarbonAI Carcinoma in Situ CardIQ Cardiac Arrhythmia Cardiac ablation Cardiac care Cardiac monitoring Cardiff University CardioMEMS Hero Cardiospermum grandiflorum Cardiothoracic surgery specialty Carduelis cannabina Caremark Caremark Rx Caris Detect Caris MI Carl Dugart Carl June Carlo Incerti Carlos Quezada-Ruiz Carole Ho Caroline Dorsa Carterra Cartography Catabolism CatalYm Catalys Pacific Catalyst Pharmaceuticals Catherine Bovenizer Cecile Guegan interim Cell Culture Techniques Cell Differentiation process Cell Shuttle Cell Shuttle platform Cell Transplantation Cell-free protein CellDx-Tissue CellOPTIQ Celldex Cellular Origins Cellular Reprogramming Cellular Tissue Celtic Center for Biologics Evaluation and Research Center for Drug Evaluation and Research Centers for Medicare and Medicaid Services Central Nervous System Agents Ceperognastat Cerberus Ventures Cerebral Adrenoleukodystrophy Cerebrotendinous Cereno Scientific Cevidoplenib Chad Chagas Disease Chance Act Changchun GeneScience Pharmaceutical Change Management Charcot-Marie-Tooth Disease Charles Fuchs Charles Ryan Charles Weissmann ChatGPT Health Chaudhuri Chechen language Checkpoint Therapeutics Chemify Chemistry42 Chemoradiotherapy Chemputation Cheryl Blanchard Cheryl Lubbert Chickenpox Vaccine Chief AI Officer Chief Clinical Officer Chief Development Officer Chief Digital Chief Health Officer Chief Marketing Officer Chief Quality Officer Chief Revenue Officer Chief Science Officer Chief Scientific Officer Chief Strategy Officer Chiesi Group Children Program Chimera organism Chimerix Chimerix acquisition China 's China approval China legal issues resolution China pharma China trial China-Derived Drug China-sourced asset Chinese Neurosurgical Journal Chinese study Cholangiocarcinoma Cholesterol Drug Cholinergic Receptors Chondrosarcoma Chordoma Chorea Chris Barry Chris Lance Chris Shibutani Christiane Bardroff Christopher Martin Christopher Viehbacher Chromatography Chromosome 7 Short Arm Chronic Care Management Chronic Condition Chronic Inducible Urticaria Chronic Inflammatory Demyelinating Chronic granulomatous disease Chronic heart failure Chronic lung disease Chronic refractory cough Cigna Cigna 's Ciliary Neurotrophic Factor CinCor Pharma Cingulate CirCLIQ Circuit Cirrus Citation City Therapeutics Civil Rights Act Clarametyx Biosciences Claris Biotherapeutics Clarius handheld ultrasound Claros facility Class Class 1 resubmission Class A Class II Medical Device Classical galactosemia Claude Allary Claude Science Claudin 18.2 ADC Claudins ClearStrand-ASD Clearmind Medicine Clesrovimab CliCr Click Therapeutics ClinVar CliniQuantum Clinical Complete Response Clinical Decision-Making Clinical Deployment Clinical Equipoise Clinical Evaluations Clinical Investigations Clinical Investigators Clinical Relevance Clinical Setback Clinical Trial Suspension Clinical Trial Termination Clinical pharmacology discipline Clinical stage finding ClinicalTrials.gov CloakLink linker technology Cloning Vectors Closed Loop Medicine Clyde Biosciences Clywedog Therapeutics Co-Diagnostics Co-Dx PCR platform Coartem Cochrane review Coefficient Bio Cognition Therapeutics Cognitive Cognitive Function Neuroimaging Cognitive function: initiation Cognitive function: planning Coherus Oncology Cohort Coinbase Coleman Colin Murdoch Collegium Collegium Pharmaceutical Colonic Polyps Comac Combined immunodeficiency disease Comirnaty Commerce Commercial Officer Committee Community Clinical Oncology Program Community Health Workers Comorbidity Comparative Genomics Compass Compassionate Use Compensation Committee Complement Membrane Attack Complex Complex Complex Regional Pain Syndromes Compliance behavior Compound MOA Compugen Computational Biology Computer Security Concentra Concern Concurrent Condition Congenital Cytomegalovirus Infection Congenital adrenal hyperplasia Congenital deafness Congenital disorder of glycosylation type 1A Congenital emphysema Congress reauthorization Congressional Hearings Connect (action) Connecticut biotech Connectivity Consent Forms Consideration Constellation platform Constitutional Challenges Consumer Consumer Behavior Continuance of life Continuous Delivery Contraceptive Implant Contraceptive methods Contract Development Contrave Controlled release Convenient CorMedix Corbus Pharmaceuticals Corcept Therapeutics' Core CorestemChemon Corneal epithelial defect Cornerstone Robotics Cornucopian Capital Corporate Update Corrective Correspondence as Topic Corsera Health Corstasis Corvus Corvus Pharmaceuticals Corxel Pharmaceuticals Cosette Pharmaceuticals Cost Control Cost Plus Drugs Cost savings programs Counsel Health Country of Wales Court of Chancery Covalent Interaction Coya Therapeutics CpcPH Craig Crews Cranial Navigation platform Craniodiaphyseal dysplasia Craving for alcohol Create Medicines Creatine Kinase Crescent Biopharma Creyon Criminal Justice Crisis Cristal Therapeutics CrossBridge Bio Crossbow Therapeutics Crown Bioscience CryoStor Cryptigen CryptoMap platform Ctexli Cu-Zn Superoxide Dismutase Cues Curapath Cure (remedy) CureVac acquisition Curevo Curevo Vaccine Curium Pharma Curon Biopharmaceutical Curve Biosciences Cushing 's syndrome Cutaneous sarcoidosis Cyclerion Therapeutics Cyclic GMP Cyclin-Dependent Kinases Cylinder Health Cynata Cyprium Therapeutics Cyprumed Cytek Biosciences Cytokine Release Syndrome Cytology diagnosis Cytomegalovirus Infections DARPA-funded initiative * * DAWN DAZALS trial DCD gene DCLRE1C gene DCT gene DDAF DDX11-AS1 gene DECODE DESTINY-CRC02 DESTINY-Lung01 DESTINY-PanTumor02 DFO DFTX DGX DIA AI Consortium DIAGNODE-3 DLBCL-1 DLL3 DLL3-targeting therapy DMC DMR-001 DMX-652 DNA Methylation DNA Repair DNA Sequence DNA Sequence Rearrangement DNA replication inhibitors DNA-damage response DNDi DNL593 DNTH DNTH212 DOGE 's DPP1 inhibitor DREAMM DREAMM-8 DSC3 gene DSO DT-101 DT-216P2 DT-9081 DTC Campaign DTX301 DURAVYU DURECT DURGA-1 DXCM DYN DYNAMIKA DYNE-251 Daiichi oncology Damon Lanphear Dana-Farber Danish pharma Danyelza Dark Blue Therapeutics Dark color Darpa DartsBio Darwazah Dasynoc Data Analytics Data Fidelity Data Lakes Data Management Data Release Data Science Data Security Data-Driven AI Databricks Datar Cancer Genetics Dato-DXd Datroway breast cancer Dave Denton David Guyer David Liu David McGuire David Meek David Schenkein Day 2 Daymark Health DePuy Synthes Deal Flow Deal Structure Decanoates Decatur Illinois December 2025 Deciparticle nanomedicine platform Deciphera acquisition Decnupaz Decreased Deep Brain Stimulation Deep Learning Deep Vein Thrombosis DeepMind DeepSearch DeepSeq DeepView System Deerfield Degrader-Antibody Conjugates Degree or extent Degrons Del-zota Delta Sleep-Inducing Peptide Dementia Research Institute Demis Democrats Dendritic Cell-Autologous Lung Tumor Vaccine Denifanstat Denmark Dennis Dean Dental Solutions Denton Department of Justice Departure - action Depemokimab Deraphan Dermatographic urticaria Dermis Derrick C. Li ; Chief Business Officer Desiccation Design Desire for food Desiree Cain Deutsche Bank Develop Developing Developmental (qualifier value) DeviceGuide Dexcom G7 Dexpramipexole Diabetes Therapy Diabetic Nephropathy Diabetic monitoring - injection sites Diagnostic Accuracy Diamond Therapeutics Diamyd Medical Diastasis Diet, High-Protein Difficult-to-Express Proteins Diffuse Glioma Digital Technology Digital Trial Digital X-ray Digital digestive health Digital innovation Digital therapeutics Digital tool Dilution technique Dimerix Dimitri Azar Diorasis Diphosphonates Diphtheria-Tetanus-Pertussis Vaccine Direct-to-Consumer Advertising Directed share Disability Disasters Disc Medicine Discipline of Nuclear Medicine Disclosure Disease Evidence Principles Dispatch Bio Disputes Distribution Dizal Dizal Pharmaceutical Doctronic Doctronic AI system Dong-E-E-Jiao Donna Haire DopApp Dopamine D2 Receptor Dorsal Dose-Limiting Doustdar DoveTree Medicines Dr. Gavin Dawe Dr. Marnix Bosch Dr. Sara Brenner Draig Dren Bio Drug Compounding Drug Development Tool Drug Evaluation, Preclinical Drug Kinetics Drug Negotiation Program Drug Overdose Drug Pricing Program Drug Repositioning Drug development costs Drug licensing Drug packaging industry Dry AMD Dual-chamber systems Duato Duet, Prenatal Multivitamins Dukoral Dupixent-in-a-pill Durability Data Duvakitug Dyggve-Melchior-Clausen syndrome Dynamic Shared Ownership Dynavax Dyno Therapeutics E-688 E-Scopics E. coli disease E100 survey E2814 E6(R3 EB613 ECG-AI ECLIPSE program ECT EDIT-401 EDNRA gene EFS gene EHA Congress EKF Diagnostics ELEVATE-44 ELP Technology ELSC ELT ELV001 ELVN EMA Approval EMA China EMBARK EMBER-3 trial EMERALD-3 EMPEROR EMPEROR Phase III trial ENCELTO ENT1 ENV-294 ENaBL Platform EO-1022 EO-3021 EOC EOS-215 EOS-984 EP'949 EP4 Antagonist ONO-4578 EP4 antagonist EP4 receptor antagonist EPCAM gene EPCORE EPKINLY EPRAD ER-100 ER-Positive HER2-Negative Breast Cancer ERAS-0015 ES-SCLC ESC25 ESGO ESK-001 ESMO IO ESO-T01 ESSDAI ETA EU AI Act health EUA EVO301 EVO756 EVOKE trial EVOKE-03 trial EVOQ EXCALIBER-RRMM EXHALE-4 EY Early Intervention (Education) Early-Stage Pipeline East Asian American East Asian Americans East Hanover 2026 East Windsor facility Ebglyss Ecnoglutide Economic Conditions Economic Growth Economic Investment Committee Edap Edenbridge Edge AI Edison Oncology Edison Scientific Editas Medicine Edotreotide Education, Medical Edward Conner Efluelda Efruxifermin Eftilagimod alfa Eight Ekterly Elasticity Imaging Techniques Election Proposal Electrocardiogram Electrocardiography, 12-Lead Electroconvulsive Therapy Electromechanical dissociation Electronic Electronic Health Records Electroporation Eledon Elektrofi ElevAAte Elevar Elevara Medicines Eli Lilly & Co. Eli Lilly ; Novo Nordisk Eli Lilly David Ricks Eli Lilly acquisition Eli Lilly competition Eligible Elinzanetant Elix Elizabeth Montgomery Elkridge facility Ella Platform Eloralintide Elrexfio Elsa Emblaveo Emergency Situation Emergency Use Authorization Emergency department patient visit Emergent BioSolutions Emi-Le Emideltide Emirati Genome Program Empower Pharmacy Empowered Empress Emrelis Enanta Enbrel Enbumyst Encapsulated (qualifier value) Encephalitis Encephalopathies Encryption End Point Endevica Bio Endocrine System Diseases Endogenous Eneboparatide Energy Score Engineer Engineering Enh3ance trial Enki generative AI Enlaza Enrollment Entera Bio Enterome Enterprise Entity Entrada Therapeutics ' Entyvio Environmental pool Enzeevu Enzyme Replacement Therapy Enzyme Therapy Eosinophilic esophagitis EpiVax Epicrispr Epicrispr Biotechnologies Epidemic Epidemic Preparedness Innovations Epigenetic Silencing Epigenic Epilepsies, Partial Epiminder Epitopea Eplontersen Equillium Equipment Equipment and supply inventories Erelzi Erica Palsis Erica Taylor Erik Atkisson Erika Porcelli Erleada Erleada apalutamide Erleada upstream data ASCO Erythropoietic Protoporphyria Escalation Eshkenazi EsoBiotec Esophageal Neoplasms Essential Tremor Ester Banque Esthetics (discipline) Estimated Estrogen receptor positive Etcamah Ethics Ethics Committees Ethyreal Bio Etiome Eua (gastropod) Eucalyptus Eukaryotic Cells Europe market European Commission approval European Group for Blood and Marrow Transplantation risk score (assessment scale) European Hematology Association European Medicines Agency European Union Evaluate report Evan Rachlin Everest Everest Medicines Everlywell Evfraxy Evidity Health Capital Evoked Potentials Evommune Evopoint Biosciences Evorpacept Evrysdi Ewings sarcoma Ex-FDA ExPEC9V Exact brand biomedical or dental material Excalipoint Therapeutics Excellergy Exciva Executive Board Executive Board Changes Executive Leadership Team Executive Order 14273 Executive Team Change Executive Vice President Exercise Exfoliation Syndrome Exit activity Exl-111 Exon Skipping Exons Expanding Expedition Medicines Experience Experimental drug Expert Systems Expiration Exposome Extencilline External Director External Ventricular Drain Eye safety EyePoint EyePoint Pharmaceuticals Eyebrow structure Eyelash Eylea biosimilar FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 FAERS FAK/ALK/ROS1 Inhibitor APG-2449 FALKON FB102 FDA-approved therapies FDA-cleared AI FDA/EMA regulatory pathways FDR FGFR1 gene FGFR3 inhibitor FIGHT China Act FILSPARI FINDER FINEARTS-HF FL-501 FOG-001 FORTE FORTIFY FORTITUDE-101 FORTITUDE-102 FOXD3 gene FREEDOM2 FSHR-targeted CAR-T/CER-T FSP FT839 FTC FUJIFILM Biotechnologies FUROSCIX FXR314 FXS6837 FY2026 Facilities Association Facioscapulohumeral Factor XI antibody Factory Faeth Falls Family Fringillidae (organism) Family suidae Fanconi Anemia Farapulse Faro Faron Pharmaceuticals Fasenra Faslodex Favorable Favored Favored Nation Fear (Mental Process) Febrile Convulsions Federal Appeals Court Federal reduction-in-force statute Federated AI Feeling content Fees Fellows Ferring Ferring Pharmaceuticals Fertility Fetal Hemoglobin Fetal and neonatal alloimmune thrombocytopenia Fetroja Fetus FibroBiologics FibroGen 's Fibroblast Therapy Fibromatosis Fibrosis Fibrosis, Liver Field Medical Fill/finish Filspari Finance Financial Stress Financial Times Findable Fine - adjective Firefly Bio Firelink platform First Half First-in-Human Clinical Trial First-in-Human Study Fiscal 2026 Flare platform Flatiron Health Flexible Flow Flow Cytometry FlowMod Flu A/B FluBlok Fluad Fluad antitrust FluidCrystal technology FluoGuide Fluzone Focal glomerulosclerosis FogPharma Food Allergy Food Policy Food, Processed For which was done Forced Vital Capacity Forma buyout Formal Dispute Resolution ( Format (qualifier value) Formation Bio Formula - diet Forte Biosciences Fortrea FoundationOne CDx FoundationOne Genomic Profiling Foundations Founders Fund Fractyl Health Francis Francis Braun Francis Crick Institute Francis Wilson Frankfurt plant closure Free Mind ' Campaign Free Nurse Program ' FreeStyle Libre Freenome Test Fresenius Freshworks Friedreich Ataxia Fujifilm Biotechnologies Fulcrum Therapeutics FulcrumSec Full-Life Functional improvement Fund I Fund III Furoscix ReadyFlow Fused structure Futility Analysis Future FutureTech II G12C inhibitors G12D inhibitor G3BP2 gene GABA A GABAergic interneurons GALA peptide GB-0895 GBS GCG GCG/GLP-1 agonist GDF8 protein, human GDUFA IV GE8820 GEMINI trial GEN1107 GH Research GH001 GHO Capital GI care GI oncology GIVE program GJB2 gene therapy GLA GLM101 GLOW2 GLP-1 medications GLP-1 pipeline GLP-1 therapies GLP-1/GIP agonist GLP-1/GIP co-agonist GLP-1/GIP therapies GLP-1RA GLPG5101 GM-2505 GMMA platform GMP GMP violations GO29781 GPC3 protein, human GPCR pipeline GPCRs GPR182 gene GPT-5.2 GRADUAL-3 GRAS GRAS Reform GRT-001 GS-0321 GS-098 GS/pan-Notch Inhibitor AL101 GSBR-1290 GSK 's GSK Emma Walmsley GSK Spero GT Medical Technologies GT801 GTPase-Activating Proteins GUB014295 GUBamy GUTC GXO Gabriel Baertschi GalNAc Galafold Galapagos layoffs Galatea Bio Galaxies Galaxy Brain Scientific Galderma Galecto Galera Therapeutics Galleri Galleri test Galux Gambling Gamma/Delta T-Lymphocyte GammaTile Gan & Lee Pharmaceuticals Garda Therapeutics Gardasil sales Garetosmab Gastric Bypass Gastrointestinal Neoplasms Gastroparesis Gate Bioscience Gateway Labs Gaucher Disease Gavi Vaccine Gdańsk Gefion AI Supercomputer Gefurulimab GemPharmatech Gemini 3.1 Pro Gemini Enterprise GenEvolutioN GenSci GenScript Piscataway Pennington Gene Expression Profiling Gene Writing Gene-Edited Genelux Corporation Genentech Vice Presidents axed Genentech infectious disease General Data Protection Regulation Generalized pustular psoriasis Generate Generation Park Generations Generative Phosphoproteomics Generic Drug Makers Genes Genesis Molecular AI Genetic Biomarkers Genetic Kidney Diseases Genetic Leap Genetic screening method Genetic testing for cancer risk Genetix Biotherapeutics Genevant Geno J. Germano Genomenon Genomic Orientation Genotype Genus Aviceda Genus Malus Genus: Coronavirus GeoVax Geoff Hamilton ; Chief Financial Officer Geographic Intersection Geographic Locations German language Geron Geron Corporation Gestures Giant Cell Arteritis Giant Cell Tumors Gilde Gilead Merck HIV Gilgamesh Gitte Pugholm Aabo GlaxoSmithKline Glenmark Glenn Coleman Glickman Glioma Global Biobank Global Health Global Restructuring Global commercial operations Globalisation Globalization Glucagon-Like Peptide 2 GlycoEra Glycomine Golden Triangle Good Machine Learning Practice Google Google Play Store Gordon Gossamer Bio Gossypium Gout GovEvents Government Shutdown Grabody-B Grace Niu Grade five rank Gram-negative infections GramEye Grand Prix Graphene Graves Disease Gray Delany Great Healthcare Plan Greater China Region Greenoaks Gregory Verdine Grin Gross margin Groupe Bruxelles Lambert Growth Differentiation Factor 15 Growth Hormone Grünenthal Guardant Health Gubra Ventures Guggenheim Securities Guidance 2024 Guillain-Barre Syndrome Guillain-Barré syndrome Gumokimab Gurunathan Gut-Brain Health GxP Gyre stock H. Martin Seidel , H2H trial H5 avian influenza H5 bird flu HAELO HCM HCP HDAC2 wt Allele HDV RNA HER2- HER2-low HER2-low breast cancer HER2-negative breast cancer HER2-positive metastatic breast cancer HER2-targeted therapy HER2-targeting antibody drug conjugate HER2-ultralow HER2CLIMB-05 HER3 HERCULES trial HERO trial HFmrEF HH160 HHS Overhaul HIF-2a HIV franchise HLFM HLX07 HLX43 HLX701 HM15912 HNGE HOOKIPA HOPE-2 trial HOPE-3 HPP HR-positive HR-positive/HER2-negative breast cancer HRR gene mutation HRS-9821 HS-001 HS-20093 HS-20094 HS-20110 HSCT HSE HSP90 Heat-Shock Proteins HSV-1 viral vector HT-SPR platforms HTGS26 HTS HU6 Haduvio Hahn Hair Analysis Hairy Cell Leukemia Haleon demerger Halle Halo brace Halozyme Therapeutics Hamed Khalili Hanmi Pharmaceuticals Hans Henrik Chrois Christensen Hansoh Hansoh Pharmaceutical Hansoh Pharmaceuticals Hantavirus Harbinger Harbour Mice technology Harbour Mice ® technology Harmony Biosciences Harout Harris Lazarre Harvard Research Harvard University Hassabis Hatteras Hatteras Opportunity Fund I Hatteras Venture Fund VII Haya HeFH Head of Growth Head of Non-Clinical Development Head of Strategy Health & Wellness Health Assistant Health Canada Health Care Sector Health Care Systems Health Data Innovations Health Data Research Service Health Data Research UK Health Equity Health Improvement Health Information Systems Health Insurance Portability and Accountability Act Health Radar Health Services Research Health Services, National Health Systems Agencies Health Workforce Health conditions:-:Point in time:^Patient:- Health education HealthCare Royalty Healthcare Payers Healthcare products Healthcare services Healthy America Heart-2 Heather Knight Helen Jones Helicon Helicon peptides Helicore Helix (Snails) Hemab Therapeutics IPO Hematological Disease Hemgenix Hemophagocytic Hemophilia B Hepatitis Delta Virus Hepatitis, Alcoholic Hepatoscope Hepcludex Hereditary Diffuse Leukoencephalopathy with Spheroids Hereditary pancreatitis Hermanski-Pudlak Syndrome Herpes NOS Herpes Simplex Infections Hers Herstellerabschlag Heterogeneity Heterotopic Ossification Hetronifly Hickory trial Hidradenitis High Drop-Out Rate High dose High-Frequency Microsatellite Instability Hikal Hikma HilleVax Hillhouse Capital Hinge Health Hippo Signaling Pathway Hiroyuki Sonoda HistoSonics exit Histone deacetylase inhibitor Histopathological aspects Hizentra Hoist device Holistic epilepsy management Holter Electrocardiography Home Testing Home Use Honeymoon Effect Hong Hongjiang Miao Hookipa Pharma Hopewell Horizon Hormone replacement therapy Hospital admission Hospital specialist Houman Ashrafian Hour House Appropriations Committee House Select Committee Houston Huahui Health Human Factors Human Glandular Kallikrein 2 Human Life Foundation Human Longevity Program Human Services Secretary Humanitarian Exemptions Humira patent expiration Hungary Huntington Disease Huyabio Hyaluronic Acid anchoring platform Hybrid AI Hybrid Care Model Hybridopa Hypercon Hyperinsulinism Hypertrophic cardiomyopathy without obstruction Hypochondroplasia (disorder) Hypocupremia Hypoglycemia Hypophosphatasia Hypothalamic structure Høiland I CAN trial I&I I&I startup IB6 IBC IBI363 IBTROZI ICANS ICER ICR Fort Lee ICU ICU bedside procedures ICU nursing shortages IDE034 IDEAYA IDEAYA Biosciences IDO1 IDS gene IDWeek IDeate-Lung01 IGA IGC IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001 IGF1R gene IGF1R protein, human IGYNTE IHC IL-13 antibody IL-17A monoclonal antibody IL-2 pathway IL-22 antibody IL-23 receptor antagonist IL-31 receptor alpha IL13 gene IL1RAP antibodies IL1RAP protein, human IL31 gene IMC002 IMM2510/AXN-2510 IMNN-101 IMPACT trial IMVT IMforte trial IMvigor011 INAVO120 INBRAIN INBRX-101 IND-enabling studies INF904 INHBE INHBE gene INLIGHT INLIGHT trial INMB INNOVOTEX INOVIO INZ-701 INmune Bio IO Biotech IPG IPS test IQLIK IRAK3 gene IRAK4 gene IRS ISAC ISB ISM-001 ISM4808 ISPPD ITK gene ITP IV-equivalent Iambic Iban language Icebergs Ichnos Glenmark Identification (Psychology) Idvynso Ifosfamide/Methotrexate/Procarbazine protocol IgG4-RD IgG4-related disease IgM antibodies Igalmi IkT-001Pro Ilant Health Illicit Drug Public Policy Illumina Ventures ImCheck Therapeutics Image Analysis Group Imagio Imaging System Imdylltra Imitation Imjudo Imlunestrant Immunai Immune Activation Immunic ImmunoForge ImmunoGen acquisition ImmunoPrecise Antibodies Immunoassay method Immunocompromised Host Immunofoco Immunoglobulin M Immunoglobulins Immunopharma Immunoprecipitation Immutep Impacts, Environmental Improved Improving (qualifier value) Imsidolimab Imvax In Vitro [Publication Type] InMed Pharmaceuticals Inadequate (qualifier) Incentives Inceptive Incheon Inclusion Incubated India 's Indiana Indiana manufacturing Indianapolis Indication restriction Individualized Indivior Indolent Non-Hodgkin Lymphoma Infant, Newborn Infections of musculoskeletal system Infectious Canine Hepatitis Inference Infinity Bio Infinity Smart platform InflaRx Inflammatory Influence Inhalation Solution Inhaler Inhibikase Inhibikase Therapeutics Inhibitor Discovery Initiative Injury due to exposure to external cause Injury of cornea Inluriyo InnoCare Innovative Health Initiative Innovative Medicine Innovent Innoviva Inovio Pharmaceuticals Inozyme Insight Insilico Inspira Technologies Instill - dosing instruction imperative Instrument - device Insurance Premiums Intas Intel INTC Intellidrop Intent Biologics Intercept Pharmaceuticals Interdisciplinary Studies Interim Analysis Interim report Interius BioTherapeutics Interleukin-2 Interleukin-23 Subunit p19 International Aspects International Drug Prices International Recognition Procedure Interoperability Interoperable Interpretation Process Interventional Urology Interventional procedure Interventional radiology Intervertebral Disc Degeneration Interview Intestinal Failure IntraBio IntraBio Ltd. Intranasal approach Intravascular Invasive aspergillosis Invest Europe Investigational Invivyd Ionis rivalry Iovance Biotherapeutics Iptacopan Ireland Iris (Eye) Irish healthcare Ironwood Islatravir/lenacapavir IsoDDE IsomAb Italy antitrust probe Biogen Italy health service Itvisma Ivory Ixchiq vaccine Ixiaro Ixo-vec Izervay J.P. Morgan JADE101 JAGX JAK/SYK inhibitor JAK1/TYK2 inhibitor JAM JAMA study JBIO JC Virus JCV JN.1-lineage JNJ JNJ-2113 JNJ-4804 JPM Healthcare Conference JPMHC JPY JS005 JSPR JUST-AAV Jack Phillips Jackson Laboratory Jacobio Pharma Jacqueline Corrigan-Curay Jade Biosciences Jaguar Gene Therapy Jaguar Health Jake Leach Jake Van Naarden James Jamie Jamila Jan Hillson Janssen Vaccines January 2026 Janus kinase 1 Janus kinase 2 Januvia Janux Therapeutics Jardiance Jason Litten Jasper Therapeutics Jeavons syndrome Jeff Knight Jeffrey Venstrom Jeito Jeito II Jeremy Levin Jeremy Shefner Jerome Jersey pharma Jersey site Jesper Jian Jiangsu Hengrui Jigani Facility Jim Lang Jim O'Neill Jiwan Joaquin Job Development Job Market Jodi Ungrodt Joe Rogan Joe Willey John Carroll Johnson & Johnson Intra-Cellular Johnson COMP360 Definium DT120 psychedelic Johnson Joaquin Duato Joint Atomic Model Joint Ventures Jonathan Arambula Jonathan Vigdorchik Jonmark Jorge Bartolome Julie Kim July July 23 July 29 Juncos June June 11 June 18 2026 June 2026 June 4 Junshi Justice Jackson Juvenile K Pro KARD KARDIA-3 KARDINAL trial KAT5 wt Allele KAT6A degrader KB801 KCNT1 gene KER-0193 KEYNOTE-671 KEYNOTE-689 trial KEYNOTE-B96 KEYNOTE-B96 trial KINECT-DCP KIR-CAR KIT KKR KLKB1 gene KMT2A gene KOASTAL-2 KOASTAL-3 KOL Insight HR+/HER2- KOL Insight Psoriatic Arthritis KOMET-017 KP-301 KP-402 KP-701 KP.2 strain KPI-012 KPV KQ Labs KRAS KRAS inhibitor KRAS-driven tumors KRAS-mutant cancers KRAZATI-12 Kaerus KaiSR Kailera Therapeutics IPO Kainova Therapeutics Kakao Healthcare Kaken Kala Bio Kalohexis Kane Biotech Kankakee Illinois Kansas City cardiomyopathy questionnaire Kaposi 's sarcoma Kappa-Opioid Receptor Kardigan IPO Karen Massey Karen Smith Karim Mikhail Karin Conde-Knape Karoo Health Kashiv BioSciences Kate Estep Kate Walsh Katherine Szarama Keir Starmer Keith Keith Vendola Kelun Ken Paxton Ken Song Kendall Square Kennedy 's Kenneth W. O’Keefe Keren Leshem Kerry Dailey Kestrel Kevin Hardage Kevin Lobo Keystone Symposia Keytruda Qlex Keytruda SC Keytruda bladder cancer Keytruda combo Keytruda combo kidney cancer Keytruda head-to-head trial Keytruda patent Khalid Nabilsi Kidney Kidney Failure Kidney Failure, Chronic Kim Kin-Hung Peony Yu Kinase Assay Kits Kinaset Kinevant Kira Pharmaceuticals Kit device Kite Pharma partnership Kite, device (physical object) Klaas Zuideveld Kleiner Knee pain Kodiak Sciences Komodo Health Kong Kong stock exchange Korea Korea market Korean language Kosmos Kostaive Kowa Kristin Bittenbender Kriya Kronos Kronos Bio Krystal Biotech Kumquat Biosciences Kv7 activator Kyle LaHucik Kymera Therapeutics Kyntra Bio Kyverna Therapeutics LAG-3 immunotherapy LAGOON trial LAPSCOVERY LAVA-1266 LBP LBS-008 LDLR gene LEAD platform LEAP District LEAP2MONO LENZ LFMD LG Chem oncology China cancer LGBTQ+ professionals LGMD2I/R9 LIGAND-AI LITESPARK-022 trial LITFULO LLM-based technology LLMs LMT15 LNTH-2501 LONP1 gene LOTIS-5 LOTIS-7 LP.8.1 sublineage LR-MDS LRP4 gene LRPAP1 gene LRRK2 gene LSCD LTBR agonist LUCE-1 LUNA 3 trial LX9851 LaNova Medicines Labor (Childbirth) Labor Unions Lancet Landscapes Lansing Michigan Lantheus Lantheus Holdings Larix Lark Health LarkVantage Lars Rebien Sørensen Larsucosterol Latex Fixation Tests Latigo Latitude PsO Launch-HTN Laverock Therapeutics Lawrenceville Lead-212 Leaders resign Leaked Lean Derisking Leapfrog Bio Lebanon Leber congenital amaurosis-4 Left atrial pressure Left ventricular ejection fraction Legal Case Legal Challenges Legend Biotech Somerset Raritan Lehigh Valley Lens platform LensAI Lenvima Lepodisiran Leqembi IQLIK Lesion Lesion reduction Letitia James Leukoencephalopathy, Progressive Multifocal Levels (qualifier value) Lewy bodies Libertas Bio Libertyville Illinois License Agreement Life Life Biosciences LifeMine LifeSignals LifeX Lifespan Extension Lifetech Lifyorli Ligand Pharmaceuticals Light AI Ligufalimab Lilly 's Lilly Buys 20B+ 2026 Lilly Jaypirca pirtobrutinib Lilly Novo Nordisk Lilly Verve buyout PCSK9 therapy Lilly inks Lilly obesity Lilly oncology chief Lilly retatrutide Phase 3 Lilly triple agonist FDA LillyDirect customers Limbal Stem Cell Deficiency Limitation Limited stage (cancer stage) LimmaTech Linac QA LinusBio Lionel Seltz Lipfendra Lipid Metabolism Disorders Lipids Lipoidosis Lipomatosis, Multiple Symmetrical Lipoprotein(a ) Liposarcoma, Dedifferentiated Liquid CDx Lisa Eli List Litespark Lithotripsy Livdelzi Live - Specimen Condition Live Biotherapeutic Product Liver Cirrhosis Liver damage Loan Logica London Bioscience Innovation Centre London Cancer Long-Term Strategy Longwood Fund Lorbrena Lorundrostat Losers Lotte Low dose Lower Profile Lower Rates Lp(a ) drug Lukas Braunschweiler Lukácsháza Luma <eudicots> Luma Health Lumina 3D Lumryz Lumvoa Lumvoa FDA Lumykras LunAIRo Lung Diseases, Interstitial Lung consolidation Lung-201 Lunit Lunit AI Lunit SCOPE Lunsekimig Lunsumio-Polivy Lupinus Lupus treatment Lutathera Lutetium-177 Lyell Immunopharma Lyfgenia Lymphatic Abnormalities Lymphocyte Count measurement Lymphocytes Lymphocytes, Tumor-Infiltrating Lymphohistiocytosis Lynavoy Lynk Lynozyfic Lyophilized Inactivated Group A Streptococcus TARA-002 Lysosomal Storage Diseases M Ventures M financing M growth fund M&A consolidation M&A transactions M&amp M-TEER M.D. M1/M4 agonist M6495 M9466 MACE-3 MAGNITUDE-2 MASLD MATCHING MATTERHORN trial MC3R/MC4R MC4R MDASE MDD MDM2 Antagonist ASTX295 MDM2 gene MDNA11 MDNA113 MDR MDR CE Mark MEERKAT trial MEK inhibitor MESA MET exon 14 skipping mutation MET protein MFLUSIVA MGI MGnify Stability Dataset MIPOGA MIPSA technology MIRACLE trial MIT MITIGATE trial MK-7240 ML-007C-MA MLTX MMRV vaccine MOG antibody disease MONARCH-E MPS MR closure MR-139 MRCT MRD MRD-negative MRM Health MS MS drug MSH5 gene MST brand of morphine sulfate MST-0312 MTLE MTX240 MTX652 MVM MWT MYB transcription factor MYO7A gene MYR301 MZE829 MaGic trial MacTel Macao Machado-Joseph Disease Machine Macular degeneration Macular retinal edema Madness Madrigal Magnet <device> Magnetic Seizure Therapy MagnetisMM-5 Magnetocardiography Mahery Mainland China Maintenance study Maintenance therapy Makary era Maker (occupation) Malignant Bone Neoplasm Malignant Female Reproductive System Neoplasm Malignant Pleural Mesothelioma Malignant neoplasm of cardioesophageal junction of stomach Malignant neoplasm of skin Malignant neoplasm of thyroid Malus domestica Manfidokimab Manifold Bio Manihot esculenta Mantelli Manufactured Supplies Manufacturer Manufacturing costs MapLight Marcel Reichen Marco Rubio Marengo Maria C. Freire Marietta Pennsylvania Marjan Farid Mark McLellan Mark Pavao Mark Stevenson Mark Turco Markers (device) Marketing Martes pennanti Martin Martin Makary Marvell Technology MRVL Mary-Elizabeth MassBio Massachusetts biotech Mastermind Platform Mastocytosis, Systemic Matchpoint Therapeutics Maternal Health Matt Buckham Matt Skelton May 18 May 2026 May 26 Mayne Mayo Clinic Mazdutide Measurement Measuring ruler, device Mechanism (attribute) MedQA MedSurg MediKarma MediView MediView XR MediView XR90 Medicaid block grants Medicaid fraud Medical Advisory Board Medical Affairs Medical Communications Medical Imaging Medical Records Medical pathologist Medicare coverage Medicare drug prices Medicare fraud Medicare reforms Medicenna Medicines Australia Medicines Discovery Catapult Medicus Pharma MedisourceRx Medivis Medline Medtronic Megadeals Megarounds Meister Melanie Ivarsson Melanocortins Melanoma TRP2 CTL Epitope Vaccine SCIB1 Meleda Disease Membranous glomerulonephritis Memo Therapeutics MenABCWY Menopausal symptom Menstruation Mental association Mentari Therapeutics Mentorships Merck 's Merck AbbVie Eli Lilly Pfizer Myers Squibb China Merck Verona Mereo BioPharma Mersana Meta Metagenomi Metals Metapneumovirus Metastatic melanoma Metastatic to Metis people Metric (substance) Michael Bierl Michael Burgess Michael Chou Michael Houghton Michael Kott Michael Langer Michael Rogers Michael Severino Microarray Analysis Microbial Microbiome SER-155 Microbiome therapeutics Microbiome-derived Peptide Vaccine EO2463 Micron Biomedical Micron Technology Microsoft Discovery Microsoft Teams Microvillus inclusion disease Miels Mikael Mikael Dolsten Mikaela Naylon Give Kids a Mike Hershkovitz Mike Sciandra Mike Stuart Mild cognitive disorder Military Hospitals Miltenyi Biopharma MindMaze MindWalk Holdings Corp. Minder system Mindpeak MinervaX MingMed Biotechnology Minghui Minimal Residual Disease Negativity Ministry of Health Mint - sweet Minxiang Zeng Mirador Mirador vasculitis Mirum Mirum Pharmaceuticals Misleading Drug Ads Missing Mission Therapeutics Mitchel Berger Mitigation Strategy Mitochondrial Diseases Mitral valvuloplasty Mitsubishi Mitsubishi Tanabe Pharma Mixed readout MoSEIC Mobile Health Mochida Pharmaceutical Modality Modeling Moderna vaccine facilities Modernization Modeyso Modic Moffitt Cancer Center Mohammed Moist Molecular Clamp technology Molecular Gates Molecular Imaging Molecular Targets Moleculin Momentis Surgical Monarez Monte Montes Montgomery County Montgomery-Asberg Depression Rating Scale Questionnaire Month of May MoonLake Immunotherapeutics Morbidity - disease rate Morgan Morgan Stanley Morristown Motion Mourenx Movantik Move GBS Forward™ Movement Mucopolysaccharidosis I Mucopolysaccharidosis III Multi-Drug Resistance Multiomics Mumps Mundipharma Munich Regional Court Mural Mural Oncology Muscarinic Agonists Muscle Tissue Muscle strain Muscle-Boosting Drugs Musk MyHealth app MyLabcorp MyOme MyPhenome Mycobacterium tuberculosis Myelin Sheath Myeloid Progenitor Cells MyoKardia Myocardial Infarction Myositis Myricx Bio NAION NBI-1070770 NCT07153536 NDA China NDA filing NEO100 NEPTUNUS-1 NEPTUNUS-2 NFX NGAL NGM NGN-401 NGS NHS NHS England NHS trial NHS-Galleri trial NIH grant NIH layoffs NIH-funded NINL gene NIO NK1/NK3 receptors NKTX NLRP3 inhibitor NMPA NMTi NON Mouse NOS1 protein, human NOVI NP-MP1 NPDR NPM1 gene NPM1-mutant NR1H4 gene NR4A2 gene NRG NRG1 gene NRTX-1001 NSCEB NTHI NTLA-2002 NUCLIDIUM NUSAP1 gene NUZ-001 NVG-291 NVIDIA 's NVIDIA Lilly NX-3911 Nabla Bio Nach01 Namandjé Bumpus NanoDisc NanoPhoria Nanobody Discovery Platform Nanomedicine Nanostructured Materials Naphthoquinones Nasal Polyps Nasal drug delivery Nasal inflammation Nasdaq ATTO Nasdaq Stockholm Nasua Natalia Misciattelli Natera National Association of National Biotechnology Conference National Cancer Institute National Priority Vouchers National Resilience National Security Commission Native (qualifier value) Natural History Study Natural killer triggering receptor, human Nature Nature Aging Nature Biotechnology AI biology Nature Biotechnology Nanovials Nature Biotechnology billion Nature Biotechnology cell-cell interaction Nature Medicine Nausea Nav1.8 inhibitors NeOnc Technologies Nebulizers Negative Negative Predictive Value of Diagnostic Test Negotiation Program Neko Health Nektar Nelson Sun ; Chief Operating Officer Nemluvio Nemvaleukin Alfa Neo-1 Neoantigen Neomorph Neumora Therapeutics NeuraClick Neural Circuit Stimulation Neural Network Simulation NeuralPLexer Neuro Disease NeuroThera Labs Neurogene Neuromuscular Monitoring Neuromyelitis Optica Neurona Therapeutics Neuropsychology Neurosteroids Neurotrophic keratitis Nevada Nevada <Geographic Area> New Approach New Approach Methodologies New Jersey layoffs New Jersey operations New York AG New York Stock Exchange NewAmsterdam NewBridge Pharmaceuticals Newborn NewcelX Nexon platform Nexplanon Next Pathways NextCure NextGen NextRNA Nextstellis NiKang Therapeutics Nia Tatsis Nick Eshkenazi Nick Vatakis Nicole Ossey Nicole Verdun Nimacimab Nimble Nimbus Niowave Nipocalimab Nippon Shinyaku Nominee Non-Hormonal Non-Incretin Non-Muscle Non-Opioid Non-Opioid Pain Nona Biosciences Nonalcoholic Steatohepatitis Nonclinical Automation Noninvasive Endpoint Noom Nordisk alliance Nordisk facility Normalize (activity) Norovirus North Chicago North Chicago Illinois North Star Ambulatory Assessment Clinical Classification Northern District Northwest Nosis Novartis ' Vasant Narasimhan Novartis Venture Fund Novartis-Chinook acquisition November 2025 Novo Holdings Novo Nordisk Plainboro NovoCare Novocure Nubeqa Nucleus RadioPharma Nulibry Numab Numerous Nura Bio Nurses Nutrition Guidelines Nuvalent buyout Nuvation Nuvation Bio Nuzolvence OAKH OASIS poly(divinyl-co-N-vinylpyrrolidinone) OBI OBT OBX-115 OCT50 OCU400 OCU410 OFA OHB-724 OHSU OIG bulletin OKYO OM336 OMass ONS-5010 ONWARD OPKO OPTIMA trial ORKA-001 ORN-252 ORNITHINE CARBAMOYLTRANSFERASE ORX142 ORX489 OSE Immunotherapeutics OTX-201 OTX-TKI OVATION OX2R agonists OX40 agonist OX40 receptor OX40L antibody OXPHOS pathway Oak Hill Bio Oberland Capital Oberon Obesity Drugs Obesity Trial Obsessive compulsive behavior Obsidian Therapeutics Ocaliva Occupational activity of managing finances Oceanside Ocedurenone October Ocugen Ocular Therapeutix OdyssION platform Officer David Rose Offit Ogilvy Health Omeros Corporation Omicron Omicron JN.1 Omnipod Omnitrope Omniverse On-Demand Events On-Demand Webinars Onapgo Once-Weekly Insulin OncoMimics Oncoinvent ASA Oncologic Oncology Collaboration Oncology Focus Oncolytic Viruses Oncotelic Therapeutics OpenEvidence Operable Brain Tumors Operating Operating expenses Operation Trailblazer Operational streamlining Operative Surgical Procedures Operator Partners Opfolda Ophthalmological implant Opiate Addiction Opioid Opioid Crisis Opioid Use Disorder Opportunity Fund III Opthea Opthea 's Opthea layoffs Optigo Biotherapeutics OptimiZe technology Optimism Optinose Optogenetic Gene Therapy Opvee divestiture Opzelura Oracle Health Oral Medication Oral Medicine Oral Wegovy Oral region Orals Orano Orbis Orbital Therapeutics Orca-T. Order Tubulidentata (organism) Organ Shortage Organisation for Economic Co-Operation and Development Organovo Ori-C101 Oricell Therapeutics Orion Group Orna Therapeutics Orotecan Orphan Cures Act Oruka Orum Therapeutics Oryon Cell Therapies Osanni Bio Oscotec Oslo Stock Exchange Osteogenesis Imperfecta Osteoporosis Ostro acquisition Otsuka 's Otsuka Holdings Otsuka Pharmaceutical Ottava Oura Genomics Oura Ring 5 Outfront Health Outlook Therapeutics Outlook Therapeutics ' Outsourcing Ovation.io Overall Publication Type Owkin Ownership Oxervate Oxford BioTherapeutics Oxford Finance Oxford spinout Oxycontin Oyster Point P-Value PACAP X CGRP bispecific PADOVA study PALSONIFY PARP1 PB212 PBA PBC PBLS PC Platform PCED PCSK9 base PCVs PD-1/VEGF bispecific PD-1xVEGF bispecific PD-L1-negative PD-L1xVEGF-A PDE4 inhibitor PDUFA VIII PER-001 PERC PERIDOT PERSEUS trial PET/CT scan PF-06954522 PF-07872412 PF-ILDs PFAS gene PG-102 PGI PGN-EDODM1 PHD inhibitor PI3 K inhibitor PI3 K inhibitors PI3 K pathway PIK3CA-driven PIK3CA-mutant PIK3CA/AKT1/PTEN mutations PIK3CA/AKT1/PTEN pathway PIKTOR PIP financing PIPE financing PIVOT-PO trial PK activator PKMYT1 protein, human PKP2-associated cardiomyopathy PMN310 PNH drug development POETYK PP353 PPF PRA023 PRC2 inhibitor PRECISE-AD trial PREVAIL trial PRISM BioLab PRMT5 gene PROGRESS-AD PROSERA PROTACs PRT13722 PRV PRX012 PSMA PSMA-targeted radioligand therapy PSMA-targeting PTAB PTEN-deficient tumors PTH1R gene PTK7 PTK7 protein, human PTRS PURPOSE studies PYNNACLE trial Pacira Pacira BioSciences Pain Palleon Palsonify Paltusotine Palvella Therapeutics Palynziq Pancreatic Ductal Adenocarcinoma Pandion Paolo Tarantino Papillary Disease Parabilis Paratek Parker Institute for Cancer Immunotherapy Parkinson Parkinson 's Part B drugs Participant Partner Therapeutics Partnering Partnering Office Pasadena Pascal Soriot Passage Bio Path-IO Patient Care Team Patient Protection and Affordable Care Act Patient Square Capital Patient data Patient education (procedure) Patient location type - Department Patient-Centered Patrick Vink Patrizia Cavazzoni Patterns Paul Edick Paul Fornazzari Paul McKenzie Paul Thomas Pavblu Payer Engagement Payspan Pazdur Peakbridge Pediatric care Pediatrics Pedro Beltran Peer-Reviewed Research Pelage Pelage Pharmaceuticals Pemgarda Pemphigus Vulgaris Pennsylvania site closure Pensions Pentagon Pentagon blacklist PepGen PepMetics Peptide API Peptide Biosynthesis Perception Perianal fistula Peripheral Arterial Diseases Peripheral neuropathic pain Peripheral neuropathy due to and following antineoplastic therapy Perjeta Perkins Permanent Peroxisome Proliferator-Activated Receptors Persica Persistent Personal Data Engine Personality Character Perspective Perturb-seq Peter Greenleaf Peyronie 's disease Pfizer 's Pfizer Albert Bourla Pfizer Astellas Padcev Pfizer Ventures Pfizer acquisition Pfizer staff Pfizer vet Pfizer walk away Pfizer-BioNTech Phagocytosis Pharma Acquisition Pharma Concessions Pharma Manufacturing Pharma Tariffs Pharma import taxes Pharmaceutical Ingredients Reserve Pharmaceutical Investment Oversight Pharmaceutical Layoffs Pharmaceutical Packaging Pharmaceutical Policy Pharmaceutical executive pay Pharmacogenomics Pharmacy Compounding Advisory Committee Pharmatech Phase 1 - 2a Phase 1 Data Phase 1 trials Phase 1/II Phase 1b/2 Trial Phase 1b/2a Phase 2 BEACON Phase 2 Failure Phase 2 HORIZON Phase 2 TRAILHEAD Phase 2 VALIANT Phase 2 data Phase 2 results Phase 2 termination Phase 2a Phase 2a Trial Phase 2b SYMMETRY Phase 2b trial Phase 3 Breast Cancer Trial Phase 3 COMPETE trial Phase 3 CREST trial Phase 3 HAELO Phase 3 INDIGO Phase 3 INDIGO trial Phase 3 PIVOT-PO trial Phase 3 RINGSIDE trial Phase 3 SENTRY trial Phase 3 SURPASS-IPF trial Phase 3 induction Phase 3 planning Phase 3 plans Phase 3 program Phase 3 prospects Phase 3 readiness Phase I – III study Phase I/II study Phase II Failure Phase II data Phase III AURORA trial Phase III Essence study Phase III MAGNITUDE trial Phase III MARIPOSA trial Phase III REGENCY trial Phase III ReSPECT trial Phase III SCLC trial Phase III ZENITH trial Phase III desmoid tumors Phenylketonurias Phesi Philadelphia Semiconductor Index Philip Brainin Phoenix Arizona Phosphodiesterase Type 4 Photoimmunotherapy Physical AI Physical Examination Physical activity Physician Executives PiNACLE Piclidenoson Pilatus Pill Penalty Pilot Pimurutamab Pinnacle Medicines Pioneer Antibody Discovery Pioneering Medicines Pipeline Review Pipeline Strategy Pitch - substance Pivotal Pivotal Trial Plainsboro New Jersey Plants Plaque (lesion) Plasma Plenary Session Plenary Speakers Plexiform Neurofibroma Pliability Plozasiran Pluri Pluvicto challenger Pneumococcal vaccine Poisons Pol Theta Polaryx Therapeutics Polivy Polpharma Biologics PolyPeptide Group AG Polycythemia Polyradiculoneuropathy Pombiliti + Pooled Sample Portal Biotechnologies Portfolio diversification Post-Exposure Prophylaxis Post-Pandemic Downsizing Post-bankruptcy consolidation Post-marketing study Poster Potentials, Event-Related Practice Experience Prasad 's Prasinezumab Pre-Clinical Model Pre-Consult Precision Pre-Exposure Prophylaxis Pre-filled Syringe Prealbumin Precision Diagnostics Precision Imaging Network PrecisionLife Predict Pregnanolone Prelude Therapeutics Premier Inc. Prescription Drug Overuse Prescription Fulfillment Presidential Symposium Preventive Health Programs Prevnar Primary Primary hyperoxaluria Primary sclerosing cholangitis Prion Diseases Priority Review Voucher Private Room Private financing Privigen ProFound Therapeutics ProMIS Neurosciences Proactive Health Probiotics Problem Probody Platform Processa Pharmaceuticals Professional guide Profiling (action) Profluent Progestins Projections Prometheus Prometheus Biosciences Promotional Claims Prompts Propel Propensity Score Prostate-Specific Antigen Prot-MaP Protara Therapeutics Protein Kinase C Protein Kinase C Inhibitor Protein Purification Protein Stability Protein, Organized by Structure Protein-Protein Interaction Protillion Biosciences Proto-Oncogene Proteins c-akt Protoporphyrin IX Provider Provider Services Proximity Prurigo Pruritus PsA-2 trial PsCatCh2.0 Pseudobulbar affect PsiThera Psoriasis of scalp Psoriatic PsyLabs Psyence BioMed Public Health Trust Public Listing Puerto Rico Pulmonary Eosinophilia Pulmonary artery pressure Pulmonary veins Pulse intelligence engine Purchase Purchased Services, Clinical and Biomedical, Calibration, Laboratory Purchased Services, Clinical and Biomedical, Research Purchased Services, Staffing, Supply Chain Purdue PureTech PureTech Health Purpura, Thrombotic Thrombocytopenic Pushechnikov Put Option Agreement Pyelonephritis Pyoderma Gangrenosum Pyzchiva Q-Scientist Q1 trends Q126 Q2 2026 Q2 layoff Q2 sales Q3 2026 Q32 Bio Q4 FY2025 QA QA102 QCS QIAsymphony QLS-111 QRS prolongation QT Imaging QTTB QUC398 QULIPTA QURE Qilu Pharmaceutical Qlaris Bio Qlex QuEEN Qualification Qualitative form QuanBio QuantHealth Quantitative (qualifier value) Quantitative Continuous Scoring Quantori Quest Analytics Quest Diagnostics Quotient Therapeutics Qureight Quviviq R&D chief R&D cleanup R&D hiring Q2 2026 R&D setbacks R&D shutdown R&D strategy R&D strategy shift R0 completely resected RACC RAS cancer RAS-addicted cancers RAS-mutated RAS/RAF inhibitor RBM39 gene RBPMS protein, human RCQ RCT RDX-002 RE104 REACH-DMD study REACtiVe-2 REDEFINE-4 weight loss REGENERATE-PD REM-422 RENOIR RESTORE-FA RET Inhibitor RET protein, human REVEAL-1 REZOLVE-AA REZOLVE-AD RFK Jr. rhetoric RFK Kennedy RG6496 RGI-C scores RIDDL RIFs RIGL RIPK1 protein, human RIPK2 RIPK2 scaffolding inhibitor RLTs RMTX RNA Splicing RNA Vaccine RNA delivery RNA drug RNA exon editing RNA gene RNA medicine RNA medicines RNA obesity RNA technology RNA test RNA therapies RNA-LNP RNA-targeted medicine RNA-targeting RNAi medicine ROR1 protein ROR1 protein, human ROS1-positive Lung Cancer ROS1-positive NSCLC ROSA Knee ROSELLA trial RP1 melanoma RPE cells RPTR-1 RQ Bio RQB01 RRP RS- RSNA RSV antibodies RSV vaccine RTU cartridges RV-8451 RVO RVU120 RVUs RWE RXRX RZLT Race:Type:Point in time:^Patient:Nominal Rachael Racism Radar Therapeutics Radiance Biopharma Radicava Radiology Specialty Radiometry Radionuclide therapy Radspherin Rahway Raised Rakuten Medical Rallybio Rallybio RLYB212 Ramp Rancho BioSciences Randomized Controlled Trials as Topic RaniPill RaniPill ® Capsule Ranluspec Ranluspec Lucentis Ranluspec ranibizumab-hkdz Ranluspec vials Rapid Edge Cloud RapidAI Ratio Therapeutics Ravi Thadhani RayThera Readiness Reading (activity) ReadyFlow Autoinjector Rebate Model Rebeca Villarreal-Barragan Receptivity Receptors, Islet Amyloid Polypeptide Reciprocal Reclassification Recludix Pharma Recognify Life Sciences Rectal Carcinoma Recurrence Risk Recurrent ovarian cancer Reduced Reflex Refractory Plasma Cell Myeloma RegFlow Regeneron Pharmaceuticals Regeneron Warren Regulation of biological process Regulatory Authority Regulatory Crackdown Regulatory Expertise Regulatory Framework Regulatory Impact Regulatory Path Regulatory Pathway Regulatory T-Lymphocytes RegulatoryFlow Reindeer Reinvent Reinvention Relapsed/Refractory Relative (related person) Relay Device Relay Therapeutics Relieving Religious Missions Relmada Relyvrio RemeGen partnership Remepy Remix Therapeutics Remote Internship Remote control command - Clear Renal function Renalys Rentosertib Rentschler Rentschler Biopharma Repair of ventral hernia Repare Reperio Health Repligen Research Alliance Corporation III Research Organization Research Projects, R-Series Research Triangle Park Reshma Kewalramani Resistance (Psychotherapeutic) Resistant hypertensive disorder Resolve platform Resources Respiratory Distress Syndrome, Adult Respiratory rate Response Evaluation Criteria in Solid Tumors Restricted Resume - Remote control command Resumption Retifanlimab Retina Retinoschisis Retreatments Retro Biosciences Retrotransposons Return on Investment Return to (contextual qualifier) (qualifier value) Reunion Island RevMed Revenue Milestone Reverba Global Reverse Stock Split Review Voucher Revita Reviva Pharmaceuticals Revolution Vibe CT Revolution daraxonrasib Revuforj Reykjavik plant Rezatapopt Rezolute Rezon Bio Rezurock Rezzayo Rhode Island Rhythm Ribo Ribupatide Richard Richard Fair Richard Gonzalez Richmond Rick Fair Rick Osterloh Rickets Ridgefield New Jersey Riliprubart Ring Sideroblast Status Rinvoq growth Risdiplam Rise Up trial Risk Reduction Ritlecitinib Rivus Pharmaceuticals Rob Michael compensation Rob Pinataro Robert Kramer Robert Malone Robert Michael Robert Warner Roche 's Roche Diagnostics North America Roche Tecentriq Roche subsidiary Rocket Pharma Rocket Pharmaceuticals Rocklin Lab Rockville Maryland facility Roctavian Roger Perlmutter Roivant Sciences Rolvedon Ron Renaud Ronald A. Williams Ronde-cel Roopal Ross Haghighat Rotation Round three Royalty Pharma Royalty-Driven Model Rubella Ruby trial Rugonersen Russia Russian language Rx refill Ryan Richardson Ryvu Rznomics S&P SABCS25 SAFEbody technology SAIL-0839 SALT score SALT score * * SANDCAT trial SARC041 SARM1 Inhibitors SASAC SASS SASTIND SAVITRI SB-01 SB36 SBA SBT-77 SBX sequencing SC0062 SC451 SCAN disorder SCLC SCLT SCN10A gene SCN1A gene SCN2A mutations SCOPE IO SCOPE trial SCOTUS SEC SEED Therapeutics SENS-501 SENTRY trial SEP-786 SERENA-6 SERON SERP-01 SERPINA1 gene SGR-2921 SGT-003 SHASTA-3 SHASTA-4 SHORE SHP-DB1 SHTG SIK2 gene SIM0505 SIM0709 SITC SKB105 SKIA SLC17A5 gene SLTE-1009 SLV-154 SLV-324 SMA SNDK SOHO SOL-1 SOLAIRIA-1 SOLAIRIA-2 SPAG8 gene SPG302 SPR720 SPR9644 SPRB SPaL SR One SRP-1003 SRP-9003 SRSD107 SSGJ-707 ST-01156 STARLYS trial STAT6 STAT6 protein STELLAR-303 trial STI-based STOMP2 STOP-V1 STOP-V2 ) STP-100 STX-001 STX-1150 STXBP1 gene SUCCESSOR-2 SUNMO SUNY AI Symposium SURMOUNT-5 Trial SURMOUNT-MAINTAIN SURPASS-CVOT SURPASS-PEDS SURVEY.ALSFRSR SVR35 SW-682 SYD-101 SYK SYNC-T Sabeen Mekan Sackler family SafeBeing platform Safety Data Safety Issues Safety labeling Sagimet Sahil V. Kirpekar Sailaja Battula Sales growth Sam Roosz Samit Samsara Samsung Bio Samsung Bioepis Samsung Health Assistant Samsung Health app San Francisco San Rafael SanDisk Sana Biotechnology Sanacor Sangamo Therapeutics Sanjay Sanjula Jain-Nagpal Sanofi Blueprint Medicines Sanofi Efluelda flu Sanofi Strategic Sanofi acquisition Sanofi flu Santen Santé Ventures Sapablursen Sapio Sapio Sciences Sapu Nano Sapu003 Sapu006 Sarah Boyce Sarah Gheuens Sarbani Sarcoidosis, Pulmonary Sarcoma, Epithelioid Sasanlimab Sasineprocel Scaling Laws Scheme of Arrangement Schott Schweizerhalle SciSparc Science of Microbiology Science of genetics Scientific Context Scientific Data Scientific Sessions ScinoPharm Sciwind Sciwind Biosciences Scorpions Scott Howell Screens (device) Scribe Therapeutics Scripps Research Seagen acquisition Seattle Office Closure Section 232 Section 301 Section viii Sector Security Measures See-Mode Self-Injectable Self-Management Self-injection Self-pay Semcap AI Semerjian Senators Send (transmission) Senile cardiac amyloidosis Senior - Suffix Seno Medical Sensei Biotherapeutics Sensorineural Hearing Loss (disorder) Sensorion Sensorion hearing loss program Sentire Surgical System Sentynl Senzime September 23 Sequestration Seralutinib Serbs Seres Sergio Marullo di Condojanni Series B fundraising Series C financing Series C funding Series D equity Series D1 Series E Series E funding Series F Series F financing Serif Biomedicines Serine/Threonine Kinases Serious Seronegative Sevaro Health Severities ShORe Shadow Shandong healthcare Shane Speirs Shankar Ramaswamy Shapes Shareholder Ownership Structure Shareholders Meeting SheMed Sherwin Sattarzadeh Shield Shigella Infections Shigella Vaccines Shin Ashida Shingrix competitor Ships Shock Shooting sensation quality Shortened Sialic Acid Binding Immunoglobulin-like Lectins Sibel Health Sickle Cell Siemens Healthineers Signal Signal Transduction Signatera SimpleScreen Simplexvirus Simufilam Single Agent Therapy Single-Domain Antibodies Siran Biotechnology SiranBio Sirexatamab Sirius Sirona Medical Sironax Sitala Site Closure Site of exit Sjögren 's disease SkinJect SkyEngine Slate Medicines Sleep disturbances Sleep medicine specialist Smart Health Map Smart contact lenses Smoldering myeloma Social Media Society for Neuro-Oncology Solid Biosciences Solubility Solutions Solve Therapeutics Solventum SomaLogic Somatix Somatosensory Cortex Sonia Sonoma Sotatercept Sotyktu BIOPHARMA South Korean biotech South San Francisco headquarters Southern Sotho language Spago Nanomedical Spain Sparrow Pharmaceuticals Spatial Mosaic Specialty pharma Specimen Spectral AI Spectrum Profiling Spevigo Spine BioPharma Spinogenix Spiriva Respimat Spondylarthritis Spravato Spravato sales Spring Health Spruce Biosciences SpyGlass Pharma ( SpyLock technology SpyTag/SpyCatcher Squamous cell carcinoma Squamous cell carcinoma of skin Squamous cell carcinoma of the head and neck Squibb Layoffs Squibb partnership Srikanth Pendyala Stabilization Stable angina Stable status Stage level 4 Staphylococcus aureus StarTrack3 Stargardt disease type 1 State Room Statement Statistical Analysis Plan Status Quo Steam Stein facility Stelara Decline Stemchymal Step Pharma Stephen Hemsley Stephen Hoge Stephen P. Dale Steve La Neve Steve St. Onge Steve Tomlin Steve Ubl Stevenage Stevenage facility closure Stimulant Stimulation procedure Stipple Bio Stock Reaction Stoke Storm Therapeutics' Strategic Brands Strategic Deals Strategic Growth Strategy Stratify Dx Stratus Strensiq Stress Stress Fractures Strive Pharmacy Structure Structure of hippocampal commissure Structure partnership Stryker Stuart Pharmaceuticals Stéphane Bancel Subacute Care Subcutaneous Cancer Sublocade Subsidies Substance Abuse Detection Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance) Substance with programmed cell death protein 1 inhibitor mechanism of action (substance) Success SunRISe-1 trial Suneet Varma Sunita Mishra Super Bowl 2025 Super Bowl ads SuperPOD Superficial ulcer Superluminal Medicines Supernus Supervisory Board Supply chain disruption Support Services Program Supportive care Supranuclear paralysis Supreme Court stay Surgeon Surgical Replantation Surgical Robot Surgical System Surgical transfer - action Surrogate Surveillance: safety Susan Susvimo Sutro Suvretta Capital Management Suzanne Winter Swift Medical Swift Ray SwiftFluo Swiss Swissmedic Swixx Group Swoop Sydnexis Sylvia Isler Symptomatic Symptoms score SynAIRgy SynKIR-110 SynKIR-310 Synapse AI Synbio International Inc. Syncromune Syncron-E Syndax Syndeio Syngene Synnovation Synthesis Syphilis, Congenital SystImmune System System User -- individual T business T cell therapy T cell-targeted T-Bolt T-Charge T-DXd T-cell malignancies T-cell therapy TA-ERT TACTI-004 TAF8 wt Allele TAILORED-AF TAK-279 TAK-921 TAS-205 TB Alliance TCEs TCR TCR-NK cell therapy TEAD2 gene TEAEs TECVAYLI TECregen TESARO TETON-2 THB335 THETA platform THRIVE-2 TIDAL-01 TIGIT antibody TIL cell therapy TJ Biopharma TKI TLN-121 TLN-254 TLN-372 TLR7/8 TLX2 gene TMP-301 TNF gene TNGX TOGETHER-PsO TPRG1L gene TR-FRET TRANSCEND TRANSCEND-T2D-1 TRBV9 gene TRCN-1023 TRD TREX1 gene TRICORDER TRIDENT trial TRIM21 TRIMTAC TRIUMPH TRIUMPH program TRIUMPH-1 TRIUMPH-2 TRIUMPH-3 TRLN TRONTIER TRPC6 inhibitor TRPV4 protein, human TRUTAKNA TRVI TRiM platform TSHA-102 TSX TScan Therapeutics TTAM TTR gene TULIP-SC trial TV ad TYK2 TYK2 Inhibitor TYR wt Allele Tace TaiGen Biotechnology Taiwan market Takeda FDA filing Takeo Takhzyro Taltz Talzenna upstream data ASCO Tampa Florida Tanabe Pharma Tang Tanruprubart Tarlatamab Tassos Gianakakos Taxes Taysha Gene Therapies Tecan Tech Rivalry TechLive Technology, Health Care Ted Love Tedopi Teijin Teladoc Health Television Tempero Bio Tempus Tenpoint Therapeutics Tenvie Tepkinly Termination - Inactive Reason Code TerraBind Terremoto Terry Fox Research Institute Test Result Testiculo- TetraGraph Texas Facility Texas Tech Thad Huston Thakkar Therapeutic Antibody Therapeutic Genetics Therapeutic Index Therapeutic Mobilization Therapeutic radiology procedure Therapeutic tactile stimulation Thetis Study Thick ThinkSono Third Circuit Court Third Harmonic Bio liquidation Third line treatment Thomas Thomas Hartung Thomson Reuters Thousand Oaks Thrive Capital Thrombotic Microangiopathies Thrombotic Stroke Thrombus Thyme Care Thyroid Diseases Tidmarsh Tim Van Hauwermeiren Time Timothy Wentworth Tinlarebant Tinnitus Tiragolumab Titania Titles Tiziana Life Sciences Tokyo Stock Exchange Tomi Sawyer Tonix Tonmya Topaz trial Topco Tortugas Toru Ashida Total Improvement Score Tourette 's syndrome Tourmaline Bio Toxic Epidermal Necrolysis Toxic Oligomers Toxicology Tozorakimab Trace Neuroscience TraceNET Tracer Tracy Beth Heg Traditional Medicine Trail Making Test Transcarent Transcranial magnetic stimulation Transdermal Route of Drug Administration Transfection Transfer RNA Transformation Officer Transformational Data Transforming RNA Medicine Development Translational Oncology Transplantation Transposition of Great Vessels Transthyretin related familial amyloid cardiomyopathy Trastuzumab Rezetecan Travel Health Travere Treatment Adherence Treatment Effectiveness Treeline Biosciences Tregs Trevi Therapeutics TriNetX Trial Phase Trial Termination TrialBlazer Trinity (ethnic group) Tris Pharma TruTCR TrueLab Biopharmaceutical Trump 's Trump administration reforms Trump administration tariffs Trump budget Trump executive order Trump floats Trump import tariffs Trump policies Trump tariff Trust (Social Behavior) Truvada Truveta report Tsingke Tukysa Tumor Microenvironment Tumor Suppression Tumor board Tumor stage Tis Tumor-Infiltrating Tumorad-01 Tumorigenicity Tumour treating fields therapy Turbine Turitz Twist Bioscience Tyler Sloat Type A meeting Type II JAK inhibitor Tyvaso Tzield U-turn U.S. Food and Drug Administration UCCD UK 's UK-US UNC13A gene UNLOXCYT UP-AA UPB UPCR US-China competition US-EU USP30 inhibitor USPTO UTP-monosaccharide-1-phosphate uridylyltransferase activity UgeneX Ugur Sahin Ultreon 3.0 Undetectable Unicorn births Unified - Type of Agreement Uninsured United Imaging Healthcare United Laboratories International Holdings Limited United States Agency for International Development Universal Universal Cells University of California Unixell Biotech Unravel Unspecified Abortion UpToDate Expert AI Updates Upstream Bio Uptake Urate Transporter 1 Inhibitor Urcosimod Urinary Bladder Urinary hesitation Urine culture Urology Urticaria Urticaria due to cold Usher Syndrome Type 1B Usona Institute Utebzi Uwe Buecheler V-01/OPA-100 trial axe VAL-413 VALOR VALOR study VAV1 protein VAX-24 VAX-31 VAY736 VAYHIT2 trial VBDS VCT220 VDPHL-01 VEGFR-targeted therapy VELO VENT-02 VENT-03 VESALIUS-CV trial VESPER-2 VHH VHH Immunoglobulin Fragments VIKTORIA-1 trial VISIONARY VISTA trial VISTAS study VITALIZE VIZZ VLA15 VMAT2 Inhibitor VMX-C001 VRDN-003 VWF wt Allele VX-993 VY1706 VY1706 gene therapy VY7523 VY9323 VYJUVEK Vabysmo slump Vaccination Hesitancy Vaccine Company Vaccine Efficacy Vaccine Reform Vaccine Testing Vadodara Vaginal Microbiome Valar Labs Valiltramiprosate Valinor Vamikibart Vanda Vanderbilt University Medical Center Vanrafia VantAI Variable (uniformity) Variant Bio Variation (Genetics) VarmX Vascular anomaly Vaseline Vasudev Bailey Vault Vaxcyte VectorY Vedana Therapeutics Veeva Systems Vega Therapeutics Veklury VelaVigo Vemircopan Ventana Medical Systems * * Venture Exchange Ventures Verastem Veraxa Verge Labs Verification Verily Verily Me Verismo Therapeutics Versant Vertex Veru Vesta <beetles> Vestibulo-Ocular Vevzuo ViVac Pharma Viatris Vibrance-1 study Vicebio Vidofludimus Calcium ViewPoint EchoPilot Viewer Device Vigil Neuroscience Viking Global Investors Villya Pharmaceuticals Vimseltinib Vinay Prasad FDA memo Vincentage Vincentage Pharma Vineet Agrawal Violence Violet AI Viome Viral Viralgen Virginia Virginia facility Virginia plant Virtual Cell Model Virtual Geneticist Virus-Like Particle Visible Vision Restoration Vistagen Visual Suppression Visugromab Vitor Roque Vivtex Voluntary Scheme Vor Bio Voucher VoxNeuro Voxzogo hip injuries Voyager Therapeutics Vunakizumab Vyglxia Vyondys 53 Vyvanse Vyvgart Hytrulo WARN WARN filing WARN notice WEE1 WEE1 inhibitor WHIM syndrome WP1066 WRN inhibitor WVE-N531 Wakefulness Test Walgreens Boots Alliance Walmart partnership War-Lock platform Warning Letter Warsaw-Duchnice Washington pushback BioSecure Act COINS Act 2025 John Moolenaar Myers Squibb Hengrui Pharma Wuxi AppTec Washington state Waukegan WeDosify Wearable Behavior Model Wearable Electronic Devices Wearable biosensors Web Site Wegovy tablets Wehr Wehr site closure Weight Watchers Weldon Weldon 's Welfare Werner Syndrome Werner helicase Werner helicase inhibitor Westborough Massachusetts Western biotech Wet AMD Wet Age-Related Macular Degeneration White House liaison Whooping respiration William Blair Wilmington Windward Bio Withdrawal Symptoms Wolfgang Wienand Wolters Kluwer Health survey Women Workforce Working Group World WorldMeds Wounds - qualifier Written - Consent Mode WuXi Biologics' Wuhu X-Cell X-Linked X-linked retinitis pigmentosa XHANCE XOMA XOMA Royalty XPro XR Xaira Therapeutics Xanthomatosis Xarelto Xarelto patent Xencor Xenograft procedure Xenon Pharmaceuticals ' Xevinapant Xianweiying Xilio Xinjiang Xolremdi Xpress Wellness Xspray Pharma XtalPi Y-mAbs Y220C mutation YARW YUVEZZI Yarrow Bioscience Yervoy Yidafan Ying Huang YolBE YolCas Yosemite Young Adult Young Talent Yvonne Greenstreet Z-1018 ZENEO® ZENITH trial ZEPHYR Phase 2 ZEPIZURE ZEUS trial ZG006 ZI-MA4 ZIMA-101 ZM-02 ZUSDURI ZW171 Zaka Zami Aberman Zanidatamab Zealand Zelgen Zelis Zelluna Zemaira ZenGUARD Zenkuda Zentalis Zentek Zepbound KwikPen Zephyr AI Zervimesine Zhongmou Zifo Zilebesiran Zilovertamab Zinc Fingers Zokinvy Zongertinib Zonsen PepLib Zoë Zuellig Pharma ZyDoc a year later aDBS aGvHD aTyr abdakibart abelacimab abemaciclib acasunlimab accelerating development accelerator acceptance access strategy accessible accretion accumulation aceclidine acquisition talks acquisition termination active pharmaceutical ingredients activin signaling acute graft acute heart attack acute systemic infection acute treatment adaptive deep brain stimulation adaptive dosing adeczibart adjunctive therapy adjunctive treatment adjuvant Tecentriq adjuvant setting adjuvant treatment admilparant administration time administrative law administrative proceedings advanced manufacturing advanced solid malignancies advanced sqNSCLC advanced therapeutics advisers advisory advisory appointments advisory meetings advisory panels aesthetic treatments affairs affinity maturation aflibercept age 2 age restriction age-related diseases agency departures agency instability agency staffing shortages aggregator agile agilon aging reprogramming aging-related diseases aglatimagene agreement rate alanyl-glutamyl-aspartyl-glycine aleniglipron all-cash tender alliance allogeneic cell therapy allogeneic hematopoietic stem cell transplant with purging alpha opportunities alpha radioligand therapies alpha radiopharmaceutical alpha-synuclein antibody alternative testing alternatives aluminum potassium sulfate ambulatory care services ametefgene parvec amezalpat amivantamab amsacrine/azacitidine/etoposide amyloid beta antibody amyloid-beta amyloid-lowering drug analytics anaphylaxis anifrolumab anitocabtagene autoleucel annamycin annualized height velocity anti-APRIL antibody anti-CD47 monoclonal antibody anti-EGFR anti-PD-1 anti-TSHR anti-VEGF therapy anti-aging anti-amyloid antibody anti-amyloid drugs anti-amyloid therapies anti-fibrotic anti-vaccine movement antibody candidates antibody collaboration antibody design antibody humanization antibody reactome antibody therapeutics antibody-chopping drug antibody-targeted antisemitism antisense antithrombin III antitrust litigation antitrust probe antitrust review antitrust verdict anvumetostat apalutamide apecotrep apical plasma membrane urothelial plaque apomorphine hydrochloride applicability application assessment appropriations approval status approval sweetener apremilast arcotatug argenx Vyvgart aroxybutynin artemether-lumefantrine artificial dyes artificial luciferases ascension aseptic manufacturing asset acquisition asset termination assumes assurance at-home at-home colon cancer at-home screening ataluren atlases atogepant atomoxetine attraction attractiveness auction autoimmune drugs autoinjectors autologous cell therapy autologous neurons autonomous avibactam avutometinib plus axon degeneration axonal degeneration azetukalner aztreonam b.well partnership backer bacterial detection baldness cure bankruptcy filing becton dickinson belumosudil bemarituzumab bempikibart benefit-risk profile benralizumab berobenatide bespoke beta version betovumeline bexmarilimab bidders bile acid therapy biliary cholangitis billing practices bimagrumab bimatoprost IOL bimekizumab binding affinity measurement biochemical recurrence bioequivalence bioequivalence facility bioequivalence study bioequivalence testing biofilm-driven chronic respiratory disease biologic blockbusters biomanufacturing jobs biomarker qualification biomarker test biomedical foundation models biomedical innovation biometric tracking biomolecular AI biomolecular structure prediction biopharma agents biopharma exit strategy biopharma financing biopharma fund biopharma industry biopharma job biopharma layoffs Q2 biopharma regulation biopharma startups biopharma survey biopharma venture biopharmaceutical company biopharmaceutical innovation biopharmaceutical partnership biopharmaceutical sector biopharmaceutical startups biopreservation bioprocess biosimilar competition biosimilar guidance biosimilar medicines biosimilarity biosimilars approval biotech IPOs biotech careers biotech closure biotech collaborations biotech crackdown biotech dealmaking biotech employment biotech executive biotech finance biotech financing biotech incubator biotech leadership biotech licensing biotech pivot biotech spinoff biotech strategy biotech workforce biotechnology innovation biotechnology layoffs biotechnology partnerships biotechnology services bipartisan criticism bird flu vaccine birtamimab birth dose bispecific bispecific antibody screening bispecific antibody technology bispecific competition bisretinoid black-box warning bleomycin/dacarbazine/lomustine/vincristine blockbuster drug blockbuster sales blocker blood biomarkers blood clotting drug blood pressure ambulatory blood pressure pill blood sugar control blood vessel disorders blood-based cancer board members board restructuring board shake-up body proportionality bone lesion prevention bonus boost booth bortezomib brain fluid brain organoids brain shuttles brain volume brain-penetrant brain-penetrant delivery brand-name brand-name drugs brand-name prescriptions branded medicines brengitecan bridging study briefing briefing documents brimonidine broaden bulks list business development priority business options business plan business practices business split business strategy business unit butyrophilin superfamily buying spree cAMPfield cDNA display proteolysis cGAS inhibitor cGVHD cUHDRS cUTI cUTIs cabotegravir calcific aortic valve stenosis calcium camlipixant campaign campaigns camrelizumab canakinumab cancellations cancer antigen therapy cancer biotech cancer diagnostics cancer drug sales cancer funding cancer intelligence cancer medicines cancer meds cancer prediction cancer proteins cancer research trends cancer testing cancer therapeutics cancer treatments cancer trials capacity quadruple capital constraints capital investment capivasertib capivasertib PIK3CA AKT pathway capsid delivery car-treg cell therapy carbachol cardiac research cardiac safety cardiac safety signal cardiac sarcomere modulator cardiometabolic care cardiorenal medicine cardiotoxicity screening cardiovascular asset cardiovascular benefits cardiovascular conditions cardiovascular deaths cardiovascular gene therapy cardiovascular program cardiovascular safety cardiovascular screening cardiovascular trial care coordination career cargo receptor ligand activity cartilage degradation carve-out casdatifan cash balance cash dividend cash-paying cell analysis cell classification cell q cell therapy sale cell therapy sales cell transfer cell transformation cell-associated neurotoxicity cell-cell project cell-device combo cell/gene therapy cellular perturbation cellular rejuvenation cema-cel cemdisiran central reads central subfield cerebrotendinous xanthomatosis cfNI software chairman resignation charmed chase checkpoint inhibitor-resistant chemical alternatives chemical modifications chemical space chemo-displacement chemo-turned-gel drug chemotherapy-free regimen chenodeoxycholic acid childhood health chinese medicine cholesterol ester transfer protein inhibitor cholesterol-lowering choline chronic disease epidemic chronic disease management chronic graft-versus-host disease chronic health conditions chronic hepatitis delta virus chronic hives chronic thyroid eye disease cisplatin-eligible cisplatin-ineligible citizen petition cityRNA civil clawback rate clazakizumab clean sweep cleavage-inducing tiny RNAs clemidsogene lanparvovec cleminorexton click clinic entry clinical dataset clinical diagnostics clinical failures clinical holds clinical improvement clinical proof-of-concept clinical queries clinical reproducibility clinical research services clinical results clinical seizure clinical terminology clinical trial conduct clinical trial halt clinical trial pathway clinical trial results clinical trial review clinical trial update clinical update clinical visualization clinical worsening clinical-stage AI startups clinical-stage biopharma clinical-stage biopharmaceutical clinical-stage biotech clinical-stage biotechnology company clinical-stage companies clinical-stage company clinical-stage immunotherapy clinical-stage pharmaceutical clinically meaningful clinicogenomics cliramitug clofutriben clone stability closed-loop interventions closed-loop systems co-development co-exclusive license co-location coalition cognition cognitive improvement cognitive side effects collaborative framework collaborative healthcare coloplast commercial supply chain commitment commitment unchanged commitments community grants community-oriented clinical trials companion diagnostics company closure company transformation compensation pharma competition codenames competition rules competitive weight loss medication complement system complete response rate complete responses composition-of-matter patent compounding pharmacy computational drug discovery computational pathology computational power computational protein design computational protocol concealment concerns safety concessions conditional approval pathway conditioning regimens confident confidentiality confirmatory study confirmatory study failure conflict of conservative criticism conspiracy constitutional challenge constitutionality consumables consumer relationship content intelligence contextual errors contingent value contingent value rights continuous continuous trial contract cancellation contract extension contract manufacturer contract research control act - information controllable controversy conversation conversion factor convertible cooperation copper histidinate copper isotopes cornea surgeon corneal endothelial disease coronary imaging coronary trial corporate development corporate governance cortisol modulator cost of care cost reduction cost-cutting initiatives cost-effectiveness cost-reduction cost-saving country-of-origin labeling covalent binding drugs covalent biologics covalent chemistry covalent drug discovery cranial neurosurgery crash craving control credit card fees critical bleeding crizanlizumab crofelemer cross-border cross-border pharma ctDNA-guided therapy curative medicines customer-facing organization customs loophole cut corners cutaneous remission cyclic adenosine-5'-trimetaphosphate cyclobenzaprine cynicism cytarabine/etoposide/methotrexate protocol cytisine cytotoxic T-lymphocyte antigen 4 daily pills daisy danegaptide dapagliflozin daratumumab daridorexant data bottlenecks data breach data gaps data generation data harmonization data misinterpretation data modernization data package data secrecy data solutions data stewardship data stolen data-driven decisions data-driven health data-driven innovation de novo miniproteins deal activity deal termination death risk reduction debt maturity extension debt obligations debut decade-long safety test deceptive deceptive marketing decision day decision science defactinib deficiencies degrader antibody conjugate delgocitinib delist delivery options demerger demyelination dencatistat depression drug deprioritization deruxtecan-nxki developmental restoration device regulation diabetes drugs diagnostic kit diagnostics industry difficult-to-treat psoriasis digital coaching digital dermatology digital enablement digital endpoints digital health ecosystem digital health records digital health regulation digital health screener digital infrastructure digital marketing digital medicine digital microfluidics digital pathology prognostic test digital quality systems digital solutions digital therapeutic digital tools digital twin diluted cardiomyopathy dimethylethylsilylimidazole direct-to-consumer ( DTC ) direct-to-employer direct-to-patient model director director firing directors disability services disciplined discounts discovery engine discovery market disease activity disease awareness disease clinical trials disease control rate disease drug disease flexibility disease program disease research disease sales disease therapies disease treatment disease vouchers disease-modifying treatment disorder control (procedure) disparagement dissolvable distributor network divestiture divestitures dolutegravir domestic pharmaceutical industry domestic production domestic supply chain doravirine doravirine/islatravir dose-response doubt downsides downsizing downturn draft report drinking levels drug activity drug ads drug affordability drug application drug approval outlook drug candidates drug combo drug competition drug conjugates drug delivery innovation drug delivery platform drug development pipeline drug development sentiment drug discontinuation drug discount program drug establishment registration drug failure drug import duties drug import plan drug importation drug imports drug ingredients drug lag drug launch drug licensing drug manufacturers drug markups drug optimization drug pipeline drug price discounts drug price negotiation drug prices fall abroad drug pricing plan drug pricing policy drug production drug quality drug rebates drug rejection letters drug rejections drug relabeling drug review reforms drug reviews drug sales drug supply chain drug-resistant drug-resistant TB drug-resistant focal seizures drug-to-data pivot dual pathway inhibition dual-agonist dual-payload ADC dual-payload technology dual-targeting dulaglutide duplicate discounts durvalumab dwarfism trial e-posters eGenesis eRNA earlier-line treatment early disease early-phase trials early-stage trial earnings beat easing ecnoglutide efdoralprin alfa efimosfermin alfa efzofitimod elacestrant elebsiran electronic health record - ActClassContainer elenestinib elinzanetant eloralintide elranatamab emergency medicine (field) emiltatug ledadotin emotional dependency employee layoffs employment employment reduction emugrobart enLIGHTEN Discovery Platform end-to-end antibody discovery endocrine disease specialist enforcement action enforcement letters enfortumab enfortumab vedotin engineered peptides enlicitide decanoate enobosarm enrollment enrollment forms enrolment ensitrelvir entera enterprise reorganization environmental enzyme engineering enzyme restoration enzyme technology eosinophil epigenetic editing epigenetic immunomodifier epigenetic modulator epigenetic therapy epinephrine equity buyback equity financing equity upside ersodetug esreboxetine estate estrogens etalanetug etanercept etrolizumab evaluation event cycle everolimus evidence-based evolocumab exagamglogene autotemcel exclusivity extension executive actions executive changes executive exits executive survey executive team executive vice president existential threats expanded label expansions expedited pathway expertise experts booted expirations exploitation external control group external controls external partnerships extrahepatic RNAi eye treatment facilities facility closure facility consolidation factor XIIa factory closure fam-trastuzumab fantasy-romance farabursen farm-to-hospital faster fat loss fat reduction federal AI federal agencies federal courts federal directives federal grants federal workers fee structure fenebrutinib fentanyl fesoterodine fibroblast immunology fibrodysplasia fibrosing fibrotic diseases fidrisertib field ablation figures filing checklist final analysis financial guidance suspension financial outlook financial recovery financial strategy financial struggles financial troubles financing strategy finerenone firi-cel firing first-in-class antibiotic first-in-human trials first-line maintenance fiscal five-year flagship office flaws flu/COVID-19 foreclosure proceedings foreign companies foreign direct investment foreign drug manufacturing foreign factories foreign investment formula update formulary exclusion formulations four-letter suffix franchise frataxin frataxin protein fratricide-resistant free trial frontline AML frontline therapy fruit-flavored vapes full-year guidance fumaric acid function funding agreement funding bill funding cut funding environment funding lapse funding rounds fungal prophylaxis furosemide gRED gallium gamgertamig gamma secretase inhibitor gamma-linolenic acid garadacimab-gxii gastric inhibitory polypeptide receptor gastroenteropancreatic neuroendocrine tumors gastrointestinal gemcitabine intravesical system gemcitabine releasing system gene delivery process gene editor gene modulation gene therapy platforms gene variants gene writing gene-editing therapy general-purpose generative design generative models generic competition generic manufacturing generic medications generic semaglutide generic tirzepatide generics revenue generics slump genetic cell genetic data genetic diagnosis genetic dilated cardiomyopathy genetic epilepsies genital lesion reduction genome engineering genome screening genomic analysis genomic drug discovery genomic medicines genomics AI genotoxicity geographic population geopolitical factors geopolitical risk gildeuretinol glatiramer acetate global commercialization global competition global competitiveness global drug development global drug pipeline global growth strategy global headquarters global health programs global health security global license agreement global network global price global research collaboration global sales global strategic R&D center global strategic collaboration global strategic partnership global strategy global trade tensions global trial global workforce reduction glycoengineering glycosylation go-to-market models golden decade golimumab government events government programs government review governmental engagement grace granite grant cancellation green energy green list green manufacturing gross profit growth Z-score growth drivers growth opportunities growth products guidance raise guidance revision guidance upgrade guidances gusacitinib hair loss treatment halt hand sensation hands-free harassment head-to-head psoriasis head-to-head trial headcount health coverage health data privacy health industry health officials health prediction health records health system partnerships health systems health tech venture health tracking health workers healthcare AI healthcare IPO healthcare IT healthcare agencies healthcare analytics healthcare appointments healthcare benchmark healthcare budget healthcare changes healthcare executive healthcare finance healthcare financial performance healthcare funding healthcare infrastructure healthcare innovation healthcare legislation healthcare marketing trends healthcare operational healthcare operations healthcare payments healthcare specialist healthcare startup healthcare trends healthcare venture healthcare workflow healthspan healthy lifespan healthy longevity heart drug heart events heart risk-benefit debate guidelines heavy drinking height velocity hematologic cancers hematologic care hematoxylin and eosin ( H&E ) stained hemophilia A program hep C pill hepatitis B functional cure hepatitis B policy change heroin herpesvirus 2, human heterozygous high-dose high-dose neurotherapy high-dose regimen high-performance computing high-profile high-risk patients high-throughput higher risk higher-value reagents highest-paid pharmaceutical CEOs hindrance hiring challenges hiring rebound hold-and-kill homegrown hormone receptor-positive hospital apps hospital intervention hospital nutrition host disease human care navigators human-relevant models huntingtin-lowering hyaluronidase hybrid intelligence hydroxyurea hyper-personalized engagement hyperscaled data iMTP iNHL iPSC-derived iPSCs iSCIB1 + iSCIB1 + melanoma immunotherapy idiopathic Parkinson 's disease illegal immigration iloperidone iluzanebart image management imaging AI immune compromise immune disorder therapy immune mapping immune profiling immune protection immune reset immune signaling pathways immune system reprogramming immune-related adverse events immuno-dermatology immuno-fibrosis immunoglobulin G immunology drug development immunotherapy drugs implantable device implementing import rules import taxes impurity in situ in vivo studies in vivo therapy incidents inclacumab incretin secretagogue incretin therapy indictment individual choice individual-based decision-making induction trials ineffective efforts infant infestation influenza prevention inhaled drugs inhaled lung disease inhaled therapies inidascamine initiation protocol injectable obesity therapy innovate innovation centre innovation grants innovation pipeline innovation strategy innovative drugs innovative medicines innovative trial inorganic pyrophosphate insider insider trading insolvency insulin delivery insulin icodec-abae insulin production integrated decision-making integrated solutions interferon pathway interleukin-11 interleukin-12 interleukin-23 receptor activity interleukin-3 interleukin-4 intermediate-risk internal disagreement internal rate internal tensions international drug international operations international pricing international trade internet phrase internship intestinal growth intisemeran intra-abdominal infections intracortical microstimulation intraoperative guidance intrathecal delivery intrathecal formulation intravenous delivery intravenous formula investing investment cutback investment grants investor rescue investor sentiment irAE isatuximab isolator technology itolizumab ixekizumab ixovec iza-bren izalontamab judgment jumping gene jumping genes juniper tar jurisdiction kickback scheme kidney drug kidney therapeutics kilobase pairs kinase inhibitor [EPC] kininogenase kyron.bio lab results lab space label extension label update labeling change labeling changes laboratory modernization laboratory reform programme lack of lack of transparency lackluster data lanifibranor large-scale manufacture laru-zova late recurrence risk late-stage assets late-stage clinical development late-stage pipeline late-stage testing lawmakers layoff leaders leadership shake-up lean muscle lecanemab-irmb legacy cancer legal victory legality lenacapavir weekly lender takeover lentiviral vector lentiviral vectors lenvatinib letrozole leuprolide levacetylleucine levodopa levy liability liability frameworks license suspension licensing restrictions lidERA life science incubator life sciences companies life sciences fund life-extension life-saving medicine likeability lincomycin linezolid liquidation live event liver enzyme elevation liver mRNA medicine liver survival loan financing localization locally advanced locally advanced head locally advanced risk long-acting injectable long-acting injectables long-acting protection long-acting therapies long-acting therapy longevity science lorlatinib loss of function loss treatment lotiglipron low low-cost lower dose lower-risk myelodysplastic syndromes lunbotinib fumarate lung scarring lunsekimig lupus skin drug lurbinectedin lymph nodes lymphocyte immune globulin, anti-thymocyte globulin lymphocyte-activation gene 3 protein lymphocyte-activation gene 3 protein, human mAbxience mCSPC mCombriax mFARS mGnP mNEXSPIKE mRESVIA mRNA contracts mRNA degrader mRNA misinformation mRNA production mRNA therapy mRNA-1083 mRNA-1283 mRNA-1647 cytomegalovirus vaccine mRNA-4359 mRNA-based mRNA-based Personalized Cancer Vaccine mRNA-4157 mRNAs mTNBC mTORC1/2 inhibitor machine learning model macroeconomic macrophage-based programmes macular maintenance phase malignancy risk malignant haematology management layers management technique mandates manufacturing campus manufacturing challenges manufacturing closure manufacturing company manufacturing consolidation manufacturing license manufacturing organization manufacturing practice manufacturing process manufacturing shutdown manufacturing uncertainty marketing approval milestones marketing authorisation marketing officer marketplace marstacimab mast cell therapy match Eylea maternal-fetal monitoring mazdutide measles, mumps, rubella, varicella vaccine measurable outcomes mechanistic trials mechanoporation med-tech median employee medical advancements medical benchmarks medical breakthroughs medical data medical device company medical documentation AI medical freedom medical groups medical jargon medical leadership medical review medical supplies medical supply chain medical technology exemptions medical wearables medtech industry meeting cancellation mega depots megascale melanin-concentrating hormone membranoproliferative glomerulonephritis men 's health menen inhibitor mental health innovation merger cancellation mesothelin metabolic dysfunction-associated steatohepatitis metabolic health metabolic medicines metagenomic sequencing metastatic solid tumors metastatic triple-negative breast cancer methylone mezigdomide mezigitamab mice studies microdosing microenvironment microneedle patches microneedles microparticle technology microservices mid-2030s mid-stage middle dose middle-income countries middlemen midline glioma midterm milestone payment milsaperidone mini-proteins minimis exemption minimization miniprotein design suite missed milestone mitazalimab mivelsiran molecular AI molecular design molecular entities molecular glue degrader molecular modalities molecular point-of-care molecular residual disease moments monogenic kidney diseases month most-favored most-favored-nation pricing motor fluctuations motor milestones mouse models movers mucosal healing multi-agent system multi-agent systems multi-cancer early detection multi-cancer screening multi-cancer tests multi-domain proteins multi-institutional research multi-medicine platforms multi-omic strategies multi-payload multi-program collaboration multi-sensor multi-specific antibodies multi-target collaboration multi-year collaboration multibillion-dollar market multiforme multimodal approach multimodal data multiple disease areas multiplex test multiport surgery multispecific antibody muscle disease therapy muscle health muscle loss muscle strength endpoint muscle-invasive musculoskeletal conditions myQA StarTrack myelin repair myosin inhibitor myostatin antibody myostatin inhibitor nAMD nHCM naloxegol naltrexone-bupropion naming convention nano-in-micro delivery nanobody nanodelivery nanosecond naproxen-n-butyl nitrate narcolepsy drug narsoplimab natalizumab nation policy national dementia registry national priorities national priority review voucher national priority review vouchers national sector growth nations natural orifice surgery naturalX nature-inspired drug discovery navacaprant navenibart navtemadlin needle-free vaccines negative adcomm negative opinion negotiators nemolizumab neo-epitope cancer vaccine neosubstrate neuro injury neuro pipeline neuro-metabolic diseases neuro-rare diseases neuro-specialty diseases neurodegeneration therapy neurodegenerative neurofibroma neuroimmune disorders neuroinflammatory neurological therapies neurology pipeline neuropathic corneal pain neuroplastogens neuroprotective neuropsychiatric disorders neuropsychiatric drugs neuroreparative therapeutics neuroscience division neurotechnology neurovascular AI neutrophil-mediated disease new product newco nexiguran nexiguran ziclumeran next-gen brain therapies next-gen pneumonia next-generation Covid vaccine next-generation RNAi next-generation drugs next-generation vaccine nintedanib ninth nipocalimab-aahu nirsevimab nizubaglustat nmHSPC nodularis nomination committee non-European ancestry non-FDA non-antipsychotic non-competitive profile non-cystic fibrosis bronchiectasis non-dilutive non-dilutive financing non-generic specialty non-hormonal therapy non-incretin therapies non-inferiority non-mRNA vaccine non-metastatic non-opioid non-opioid pain medication non-opioid pain relief non-opioid pain therapies non-relapsing secondary progressive non-surgical back pain non-ultrasound-trained operators noncirrhotic nonclinical reporting nonprofit webinars nonrelapsing nonresponder nonsurgical treatment options normative wakefulness nucleic acid delivery nusinersen obesity therapy obesity-related cancers obsidian ocadusertib ocular adverse events ocular delivery ocular immunology off-target offerings office closure offloading offshore older children oligomer selectivity olorofim olverembatinib omnichannel on-demand once-daily pill once-daily tablet once-weekly once-yearly oncology acquisition oncology advancements oncology collaboration oncology combo oncology company oncology decisions oncology diagnostics oncology ecosystem oncology expert oncology licensing deal oncology market oncology pivot oncology portfolio oncology supply oncology therapeutics oncology trials oncolytic immunotherapy online program ontunisertib open innovation open science open-label extension open-source AI open-source dataset openFDA operating costs operating expenses operating profit margin operational efficiency operational transformation optimisation programme opto-acoustic imaging oral FASN oral PCSK9 oral asthma therapy oral carbapenem oral cholesterol pill oral drugs oral formulations oral hair loss oral inhibitors oral minoxidil oral obesity drug oral peptide oral pill oral pill vaccine oral presentation oral regimen oral small molecule RNA degrader oral small-molecule therapeutics oral small-molecule therapy oral targeted therapy oral weight loss drug orchestration orelabrtuinib orexin agonist orexin receptor type 2 organ donor organic growth orglipron orphan drug exclusion orthopedic innovation osavampator ossificans otoferlin out-licensing outbound investment over-reaction overall response rate overcapacity overhangs overhaul overhype overmedicalization overseas oversubscribed oversubscribed fund ownership increase ozekibart ozureprubart p-tau217 p53 reactivator pTau217 packaging issues pain assets pain crises palivizumab pamirtecan pan-JAK inhibitor pan-KRAS pan-TEAD inhibitor pandemic influenza paradigm partial response partnering with pasritamig patent expiration patent license pathology AI patient definition patient management patient meals patient navigation patient populations patient recruitment patient-provider interaction patient-specific therapies patient-specific therapy patient-ventilator asynchrony patritumab pattern hair loss pause recommendation pay-for-delay payer paying payload payors peak sales pediatric brain cancer pediatric diseases pediatric dosage pediatric drug designation peer pelareorep penicillin recall pent-up demand peptide therapeutics performers perioperative therapy permanent role personal data personal genome service personalized cancer therapy personalized care personalized health services personalized healthcare personalized neuromodulation personalized treatment personnel change perspectives pertuzumab petition pharma TV ads pharma biggest company pharma brand engagement pharma companies pharma consolidation pharma directors pharma division pharma industry pharma investment pharma investments pharma packaging pharma patent expirations pharma policy pharma reforms pharma reshoring pharma response pharma skills shortage pharma tech pharma trade group pharmaceutical AI pharmaceutical advertising crackdown pharmaceutical backing pharmaceutical collaboration pharmaceutical commercialization pharmaceutical communications pharmaceutical delays pharmaceutical delivery pharmaceutical divestment pharmaceutical drug discount resistance pharmaceutical earnings pharmaceutical employment pharmaceutical imports pharmaceutical investment pharmaceutical investment Germany pharmaceutical lawsuits pharmaceutical leadership pharmaceutical licensing pharmaceutical lobby pharmaceutical market pharmaceutical mergers pharmaceutical milestones pharmaceutical rebates pharmaceutical revenue pharmaceutical setback pharmaceutical setbacks pharmaceutical trade pharmaceutical trade war pharmacy platform pharmacy reimbursement phase 2/3 trial phase 3 POIESIS trial phase 3 failure philanthropy phosphodiesterase 4B physiological aspects physiological chemistry pilot data pimecrolimus pipeline blips pipeline cull pipeline gaps pipeline management pipeline restructuring pipeline setbacks pipeline shake-up pipeline shift pipeline update pipeline work pivekimab sunirine pivot resources pivoxil pizuglanstat placebo-adjusted improvement plant construction plasma-derived therapies plasma-derived therapy platelet levels platform immunotherapy * * pledge plozasiran pneumococcal conjugate vaccines pociredir podcast political politicization poly-N-4-vinylbenzyllactonamide poly-refractory rheumatoid arthritis portfolio companies portfolio prioritization portfolio reprioritization portfolio support posdinemab post-COVID post-hoc analysis post-marketing requirement post-marketing studies postprandial povetacicept pozdeutinurad practice expense practice-changing pre-IPO pre-IPO ' pre-commercialization precision neurology preclinical CRO preclinical assets preclinical drug preclinical drug discovery preclinical program preclinical research preclinical studies pregnancy detection pregnancy screening preliminary assessment preliminary injunction prescribers prescribing habits prescribing rules prescription drug ads prescription renewals prespecified pretomanid prevention antibody preventive healthcare preventive services panel price controls price decline price drop price hike price transparency price-fixing pricing flaw pricing policies pricing practices pricing pressures pricing reform prifemilast primary endpoints primary listing prioritization priority brands priority vouchers private block trade proactive care product hopping product strategy profit margin profitability programmable RNA medicines programmable biology progressiva project cancellation proof-of-concept study propane propiolactone protections protein compounds protein drug discovery protein elimination therapeutics protein expression platform protein folding protein levels protein science protein structures protein-based vaccine protein-ligand datasets protein-ligand prediction provider operations pruritus treatment pseudobulbar psychedelic medicine psychedelic mental health market psychedelic supply psychedelics guidance psychiatric trials psychiatry pipeline public biotech public companies public company public health agencies public health crisis public health debate public health guidance public health leaders public servants pulmonary disease spinoff pulsed field ablation pure-play strategy qAF quality assurance quality control violations quantitative autofluorescence quantum phenomena radiation-free imaging radical transparency radiographic remission radioisotope facility radioisotope supply chain radiological imaging radiology pathology radiotheranostics radiotherapeutic radiprodil ransomware rare blood disorder rare disease rates reimbursement ravulizumab reSET (device) readout real-estate real-time real-time clinical trials real-time disclosure real-time publishing realistic medical scenarios rebate rate rebate schemes rebranding reciprocal tariffs recognition recombinational repair record sales recurrence-free survival recurrent astrocytoma redesable eye drop reduction in force reform refractory large B-cell lymphoma refractory myeloma refusal-to-file regenerative cell therapy registrational registrational study registrational trial regulatory AI frameworks regulatory RNA regulatory advocacy regulatory agency regulatory alignment regulatory barriers regulatory certainty regulatory change regulatory changes regulatory complexity regulatory consulting regulatory decision regulatory disclosure regulatory dynamics regulatory easing regulatory governance regulatory harmonization regulatory hurdle regulatory innovation regulatory law regulatory meetings regulatory reform regulatory reforms regulatory risk regulatory sandbox regulatory standards regulatory streamlining regulatory submissions regulatory transparency reinstatement relapsed/refractory B-cell non-Hodgkin lymphoma relapsed/refractory large-B-cell lymphoma relapsed/refractory multiple myeloma relatlimab remission rate remote scanning remternetug remyelination renal response renewal representatives reproductive health biotech repurchase reputation rescheduling rese-cel research discontinuation research instrument development research partnerships research program research retraction research study research universities resignations resource shortage respiratory vaccines respiratory virus season restore restraining order restricted population restrictions restructuring charges resume analysis revakinagene taroretcel-lwey revamp revenue dip revenue goal revenue guidance cut revenue target revumenib revyve rezafungin ribonucleoside-diphosphate reductase activity rilvegostomig risankizumab risedronate risk factors risk-based risk-based oversight risperidone risvodetinib risvutatug rezetecan rituximab rivalry rivals square robotic HIFU robotic automation robotic knee replacement robotic platform roll-ups romantasy ' rondecabtagene autoleucel roundtable royalty acquisition royalty management royalty monetization rubrics runway rural healthcare sBLA sHTG sacituzumab govitecan-hziy safety signal salanersen sale rule sales guidance sales milestones sales outlook salicylhydroxamic acid sample stabilization satralizumab scFv scPharmaceuticals scSurvival scale-up scaling not solving scandal scenario school meals science-led storytelling scientific advisors scientific discovery scientist protest screening program search behavior seasonal flu second quarter 2026 secondary blood cancers secondary endpoint secondary markets secrecy China sector rotation secured secured debt securities securities fraud seed financing seed investments seizure drug seladelpar self-administered drug self-administration self-collection devices self-injectable self-injection business self-injection systems self-paying self-serve self-service selloff selpercatinib semax semiconductor supply chains semiconductor tariffs sensor (device) sequence-based AI serono setrusumab sevasemten seventh shadow AI shakeup sham surgery sham-controlled trial shareholder value shelf registration statement shortage shot marketing shrinking shrinking budgets shutdowns shuttles sialidase fusion protein sigma-2 receptor single dose single-cell RNA sequencing single-dose vials single-port surgery sirolimus site closure site transfer sizing kit skin clearance sleep biotech sleep-inducing peptide slow awareness slower small molecule agonists small molecule candidates small molecule design small molecule drug discovery small molecule drugs small molecule inhibitors small molecule medicines small molecule therapies social disadvantage software-as-a-medical-device soles psoriasis solid cancers solid tumor cancer solid-state batteries soluble NSF attachment protein activity somatic genomics somato-cognitive action network somatropin sonefpeglutide sonesitatug sonrotoclax soquelitinib sorfequiline sortilin sotatercept-csrk spatial profiling spatial proteomics specialty brands specialty diseases specialty drugs specialty endocrinology spectral imaging spesolimab spin-out spinoff spleen exam splice correction splicing correction spotty complaint reporting staff exclusion staff reduction staff reorganization stage IV reduction stake sale stalking horse stance standards characteristics starter dose statistical methods stealth stem cell-derived islet cells stem cell-secreted proteins sterile cartridge facility sterile manufacturing steroid-sparing stock price stock purchase stock repurchase programs stock sale stock sales stock slide stock slip stockholder stockpile stockpiling strain Big Pharma market pressures strain selection strategic advisory strategic alignment strategic assets strategic collaborations strategic decision-making strategic investors strategic options strategic overhaul strategic pivot strategic plan strategic reserves strategic transformation strategy streamlined process streamlined review streamlined system stroke trial structural changes stuttering pipeline subcutaneous administration subcutaneous elegrobart subcutaneously delivered antibodies sublingual tablets submission delays submission program suboptimal response subscription cancellation success rates succession planning suicide suicide warnings sunitinib sunvozertinib superbugs supercomputer superiority trials supplemental approval supply chain exposure supply chain management supply chain resilience supply chains supply shortages supply suspension suppurativa surgical guidance surgical planning surgical robotics surrogacy surrogate endpoint surveillance aspects survival data survival extension survival hazard ratio survival rate sutacimig suvorexant sweat sensors synovial fibroblasts synthetic construct synthetic royalty syphilis treatment tarcocimab tedromer target-effector pairs targeted alpha therapies targeted alpha therapy tariff avoidance tariff exemptions tariff increase tariff pause tariff threat tarlatamab-dlle tau therapy tau-targeted therapies tau-targeting tau-targeting antibody tau-targeting drug tavatecan team shutdown team transformation tebipenem tech partnerships technology innovation technology summits teen suicide telehealth platform tenofovir tenofovir disoproxil fumarate tenure terabytes terminated - RoleStatus therapeutic development therapeutic diversification therapeutic payloads therapist thermal imaging theta/beta ratio third quarter third-party facility three-year thrombotic disease thymic stromal lymphopoietin thymus regeneration thymus-targeted thymus-targeted therapy ties time acceleration tissue models tobevibart tominersen top-selling drugs topical amitriptyline topical treatment topotecan total health toxic bacteria toxicity profile trade agreement trade compliance trade deficit trade deficits trade policy trade secrets trading training data trans-splicing ribozyme transatlantic trade transdermal cannabidiol gel translational translational biology transposons transthyretin-mediated amyloid cardiomyopathy trauma qualifier traveler treatment approval treatment discontinuations treatment prediction treatment resistance treatment scaling treatment-resistant hypertension trebled treg cell therapy trial results trial site irregularities triple hormone receptor agonist triple seronegative triple therapy triple-G drug triplet combo liver cancer triplet therapy tumor agnostic tumor control tumor response tumor shrinkage tumor-specific antigens tumor-targeting engagers turbulence turnaround strategy twice-daily twice-yearly two-year survival data type I uACR uUTIs ultra-long acting ultra-rare disease ultra-short regimen ultrasound AI software unanimous vote unapproved underregulated unicorn startup union strike universal recommendation university lawsuit unmet unreliable unreported deaths unwinding policies upfront cash upfront discounts upgrade upheaval upper-limb weakness upper-to-lower body segment ratio upstream data urgent care visits urothelial cancer ursodiol utilization qualifier uveitic macular edema vIGA-AD vaccine advisors vaccine advisory panel vaccine agenda vaccine alternatives vaccine approval vaccine delivery vaccine framework vaccine guidelines vaccine industry vaccine injuries vaccine licensing vaccine marketing vaccine misinformation vaccine oversight vaccine pipeline vaccine policy vaccine programs vaccine regulation vaccine skepticism vaccine standards vaccine trial valbenazine valley of death value maximization value-based contracts value-based pricing valve disease varegacestat vascular deposit binding vascular intelligence vascular intervention vascular leakage vaso-occlusive crises vector vectorized veligrotug vendor-agnostic ventilator waveform analysis software verekitug vial stopper defects vidofludimus vilobelimab violation viral shedding viral suppression virtual care model virtual diagnosis vision improvement visual computing vitamin B12 vobra volixibat von Willebrand Disease vopimetostat vorolanib vote voting voxelotor wage waveLINE-003 wear time wearable biosensor wearable regulations wearable sensors wearable technology healthcare wearables market web navigation webinar calendar webinars weight loss business weight loss data weight loss maintenance weight loss market weight loss medication weight loss obesity weight loss therapy weight maintenance weight regain welireg keytruda kidney cancer wellness apps * * white glove delivery white space whole-virus wind-down operations windfall wireless withdrawal of approval withdrawal proposal workflow automation workforce workforce termination workplace toxicity world 's xanomeline/trospium yarrow flower extract yruvate Kinase Activator [EPC] z-rostudirsen zelenectide zelicapavir zenocutuzumab zetomipzomib ziclumeran ziltivekimab zocilurtatug pelitecan zoldonrasib zoliflodacin zongertinib zopapogene imadenovec-drba zorpocabtagene-autoleucel ( zovegalisib Élancé

Show more Show less

Powered by Blogger

X-Data LLC